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“Major breakthroughs often come after major breakdowns”  







Behavioral phenotypes beyond core symptoms of diagnoses have become an area of high 
interest in psychiatric research. All major psychiatric diagnoses are associated with deficits 
in cognitive function, including impairments in social abilities, which contribute to great 
suffering and have a negative impact on the everyday life. Aberrations in the central 
serotonin system has been demonstrated in several psychiatric disorders. However, 
treatment targeting cognitive impairment is lacking due to limited understanding of 
neurobiological mechanisms in psychiatry. The overall aim of this thesis is to investigate 
associations between cognitive ability and serotonin transporter and serotonin receptor 5-
HT1B in major depressive disorder (MDD), autism spectrum disorder (ASD) and in non-
psychiatric control subjects.  
In Study I, ten patients with MDD were examined with cognitive tests and positron 
emission tomography (PET) and the radioligand [11C]AZ10419369 binding to 5-HT1B 
receptor before and after Internet-based cognitive behavioral therapy (ICBT) and for 
comparison with ten matched control subjects. The results showed improvements in verbal 
fluency from baseline to follow-up in the patient group. Correlations were found between 
improvement in verbal fluency and changes in 5-HT1B binding in ventral striatum and 
amygdala as well as between cognitive flexibility and dorsal brainstem, amygdala and 
hippocampus. In the control group when controlled for age and education level, an 
association between visuo-constructive memory and 5-HT1B availability in dorsal brainstem 
was demonstrated. The finding implicates a positive association between improvement in 
executive function and change in 5-HT1B binding in the MDD group.  
Study II investigated cognitive performance and the serotonin transporter (5-HTT) 
availability with PET and the radioligand [11C]MADAM in fifteen adults with ASD and 
fifteen matched control subjects. Analyses revealed lower 5-HTT availability in several 
brain regions in the ASD group compared to the controls. Also, positive associations 
between social cognition and 5-HTT binding were demonstrated. These results are in line 
with the hypothesis of lower brain 5-HTT binding in individuals with ASD, and further 
supports the theory of serotonin involvement in ASD neurodevelopment.  
In Study III, cognitive ability and 5-HT1B receptor binding with PET and the radioligand 
[11C]AZ10419369 were examined in 43 healthy control subjects. Our aim were to replicate 
parts of Study I as well as explore if other cognitive domains were associated with 5-HT1B. 
The findings between visuo-constructive performance and 5-HT1B receptor binding in the 
dorsal brainstem from Study I could not be replicated. Exploratory analyses when not 
controlled for age, revealed positive associations between visuo-constructive memory and 
5-HT1B binding in several brain regions as well as negative correlations between 5-HT1B 
binding in numerous brain regions and cognitive flexibility and reaction time. When 
controlling for age effects, negative correlations between reaction time and 5-HT1B 
availability remained. Since a negative correlation between reaction time and amount of 
errors was found, implying faster reaction time and poorer impulse inhibition, these 
findings suggest that 5-HT1B receptors are involved in impulsive behavior.  
In Study IV, we investigated autism-related cognitive functions and the serotonin 
transporter (5-HTT) as well as serotonin receptor 5-HT1B with PET and the radioligands 
[11C]MADAM and [11C]AZ10419369 in a sample of healthy participants. In the 5-HTT 
sample, positive correlations between social cognition and standardized 5-HTT binding in 
striatum and putamen, as well as a negative correlation between social cognition and 
standardized 5-HTT binding in brainstem, were demonstrated. In the 5-HT1B sample, a 
significant correlation between central coherence and 5-HT1B binding in thalamus was 
found, but after controlling for age effects the correlation did not remain significant. The 
results of 5-HT1B binding in autism-like cognition do not support an association. Together 
with our finding of brain 5-HTT binding in relation to social-cognitive ability in 
neurotypical controls, and previous literature of individuals with ASD, a neurobiological 
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Psychiatric disorders are associated with great suffering influencing cognitive, behavioral 
and social aspects, reduced quality of life, and higher risk of mortality and suicide 
(Beautrais et al., 1996; Rapaport et al., 2005; Van Heijst and Geurts, 2015). Literature to 
date reveals high prevalence, with psychiatric disorders accounting for nearly thirteen 
percent of the global burden of disease, exceeding both cardiovascular diseases and cancer 
(World Health Organization, 2004; Collins et al., 2011). Nevertheless, development of 
existing psychiatric treatments as well as discovery of new options addressing clinical core 
symptoms have remained relatively unchanged over the past 30 years.  
Besides clinical core symptoms, psychiatric disorders are also associated with cognitive 
impairment. Patients report cognitive deficits of varying severity, including attention, 
different aspects of memory, learning, processing speed, visuospatial ability, and executive 
functions with verbal fluency, planning, decision-making and cognitive flexibility as well 
as impairments in central coherence and social cognition with theory of mind. Within the 
spectrum of psychiatric disorders, cognitive deficits were initially mainly associated with 
schizophrenia. However, such impairments have also been acknowledged in other 
disorders, including anxiety disorders, bipolar disorder, obsessive compulsive disorder 
(OCD), posttraumatic stress (PTSD), anorexia nervosa, borderline personality disorder, 
major depressive disorder (MDD) and autism spectrum disorders (ASD)(Jolliffe and Baron-
Cohen, 1997; Millan et al., 2012; Lang et al., 2014; Goueli et al., 2019).  
Hence, cognitive deficits are widespread within the psychiatric field. However, treatment of 
this domain has proven to be difficult. Pharmacological interventions targeting cognitive 
symptoms are lacking due to limited understanding of neurobiological underpinnings.  
Psychiatric neuroimaging research implicates a role of the neurotransmitter serotonin in 
several mental disorders, such as schizophrenia (Rasmussen et al., 2010), OCD (Perani et 
al., 2008), MDD (Gryglewski et al., 2014), anorexia nervosa (Bailer et al., 2007) and ASD . 
Moreover, associations between serotonergic markers, mainly the serotonin transporter, and 
the serotonin receptor subtypes 5-HT1A and 5-HT2A, and cognitive functions have been 
demonstrated. However, despite slowly growing body of evidence, the neurobiological 
mechanisms are still elusive. 
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1.2 MAJOR DEPRESSIVE DISORDER 
Major depressive disorder (MDD) is a highly prevalent (lifetime prevalence of 4-10%) and 
burdensome condition (Kessler et al., 2009) considered to be the leading cause of disability 
worldwide (World Health Organization, 2017). The gender distribution in MDD is skewed 
with approximately twice as many affected women than men. Studies have showed that this 
gender difference accumulates during late adolescence, and is relatively constant into old 
age (Kuehner, 2017).  
The diagnosis of MDD is based on nine symptom criteria of persistent low mood, loss of 
interest and/or energy, sleep problems, weight change, psychomotor agitation, rumination, 
cognitive impairment and suicidal ideation (American Psychiatric Association, 1994). To 
fulfill the diagnosis, at least five criteria are required, where at least one of these five is low 
mood or loss of interest. Hence, it is a clinically heterogeneous disorder with high variation 
in symptom profiles within the same diagnosis (Fried and Nesse, 2014). It has been 
implicated that some MDD criteria add unnecessary diversity to the diagnosis and are not 
specific enough. However, when investigating the psychometric properties of MDD 
criteria, all nine criteria have been shown to significantly contribute to MDD with highest 
odds ratio for low mood (OR: 61.2) and loss of interest (OR: 29.7) and lowest odds ratio for 
suicidal thoughts (OR: 8.2)(Zimmerman et al., 2006).  
Besides clinical core symptoms, cognitive deficits are also important and common. 
Individuals with MDD show a broad range of impairment across different cognitive 
domains, including attention, memory, visuo-spatial ability, processing speed, and 
executive function with verbal fluency, inhibition, reasoning, and cognitive flexibility 
(Fossati et al., 2003; Porter et al., 2007; Ahern and Semkovska, 2017). Some of these 
abilities normalize after a depressive episode, including memory, processing speed, 
learning, shifting ability, and general intellectual ability (Behnken et al., 2010; Ahern and 
Semkovska, 2017), whereas others are more persistent, such as executive function with 
verbal fluency and inhibition (Ahern and Semkovska, 2017). A longitudinal study showed 
persistent impairments in verbal fluency and inhibition at nine months follow-up as 
depressive symptoms declined when compared to a control group (Schmid et al., 2011). 
Moreover, a meta-analysis including 27 studies, demonstrated residual cognitive difficulties 
of attention, working and verbal memory, processing speed and executive function after 
clinical remission (Bora et al., 2013). Recent findings suggest that residual cognitive 
impairments increases with number of depressive episodes (Semkovska et al., 2019) 
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Available treatment for MDD involves both psychological and pharmacological 
interventions. There are various psychological interventions for MDD treatment, including 
cognitive behavioral therapy (CBT), which has been shown to be highly effective 
(Hofmann et al., 2012). CBT refers to a set of interventions focusing on maladaptive 
emotions, thoughts and behaviors. The treatment consists of techniques, including 
behavioral activation, cognitive restructuring and exposure, in order to reduce depressive 
symptoms and improve level of everyday functioning. Also, pharmacological treatment 
options are available, where selective serotonin reuptake inhibitor (SSRI) is a widespread 
and well-used antidepressive drug reducing depressive symptoms (Jakobsen et al., 2017), 
but however, fails in treating cognitive deficits. Existing, but however limited, 
pharmacological research of antidepressant effects on cognition in MDD patients suggests 
improvements in some cognitive functions, such as processing speed, delayed recall and 
verbal learning (Rosenblat et al., 2015; Bennabi et al., 2019). Nevertheless, the exact 
underlying neurobiological mechanisms are still partly unknown, which hampers the 
progress of developing successful treatment targeting cognitive impairment in MDD.  
1.3 AUTISM SPECTRUM DISORDERS 
Autism spectrum disorders (ASD) are heterogeneous, heritable, complex and life-long 
neurodevelopmental conditions with a prevalence of approximately 1.5% (Baxter et al., 
2015). The disorder is defined by impairments in social interaction and communication as 
well as stereotypic, restricted behaviors and interests from early childhood.  
Autism-like traits are considered to be continuously distributed in the population, where 
clinical ASD symptoms represent extremes on the continuum (Lundström et al., 2012). A 
high proportion of autistic-like symptoms have been identified in the psychiatric 
population, including schizophrenia (Frith and Corcoran, 1996), bipolar disorder (Santos et 
al., 2017) and eating disorder (Carton and Smith, 2014). Psychiatric comorbidity in ASD is 
high. The overlap between ASD and other neurodevelopmental disorders including 
attention deficit hyperactivity disorder (ADHD) and intellectual disability is common and 
well-described (Lai et al., 2014). Also, co-occurring mood and anxiety disorders are highly 
prevalent in the ASD population (Hofvander et al., 2009; Mannion and Leader, 2013; Lai et 
al., 2014). A study examining psychiatric comorbidity in young adults with Asperger 
syndrome, demonstrated that 70% av the participants had experienced at least one MDD 
episode, and 50% had experienced several MDD episodes (Lugnegård et al., 2011), which 
can be compared to the lifetime prevalence of 4-10% in MDD (Kessler et al., 2009). 
Possible explanations to the high MDD overlap may be an increased vulnerability in 
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individuals with ASD than the general population, with suggestions of secondary 
depression due to growing up with ASD, overlapping diagnostic symptoms or shared 
genetic and familial vulnerability. Neurobiological findings point also to neural aberrations 
in ASD, including the serotonin system.  
Concerning cognitive aspects in ASD, there are in particular three domains where 
impairments have been found – executive function, theory of mind and central coherence. 
Individuals with ASD tend to perform worse on executive function tasks when compared to 
neurotypical controls (Demetriou et al., 2018) as well as in comparison to subjects with 
ADHD in tests measuring executive functions of cognitive flexibility, but also processing 
speed (Fried et al., 2016). When comparing the cognitive construct of theory of mind, 
findings frequently demonstrate that individuals with ASD have difficulties in recognizing 
others mental state when compared to neurotypical controls (Baron-Cohen et al., 1985). 
This decreased ability to interpret and predict social situations leads to social challenges, 
consistent with core symptoms of ASD. However, the concept of theory of mind does not 
capture the difficulties with non-social cognition. Individuals with ASD show difficulties in 
getting caught in details and making the details cohere within the context, which is a 
cognitive style called weak central coherence (Frith and Happé, 1994). On the other side, 
weak central coherence could also be beneficial, where individuals with ASD show 
superior performance in tasks where local processing is advantageous (Shah and Frith, 
1983, 1993). 
 
Behavioral interventions for ASD are available, such as social skills training (low to 
moderate effect) or vocational intervention focusing on work-related support (insufficient 
effect)(Lai et al., 2014). Other treatment options are psychotherapy or pharmacotherapy 
addressing comorbid disorders, such as MDD or anxiety, which show positive effects 
(Sizoo and Kuiper, 2017). Also, medications can be used to alleviate specific symptoms, 
such as SSRI for reducing repetitive behaviors in children (Soorya et al., 2008). However, 
pharmacological options targeting the core symptoms of social communication in ASD are 
still lacking.  
1.4 COGNITIVE AND SOCIAL BEHAVIORAL PHENOTYPES IN PSYCHIATRY 
Cognitive deficits are not only very common across most psychiatric disorders, it is also 
important in predicting treatment response (Park et al., 2020), course of illness (Vicent-Gil 
et al., 2018) and treatment outcome (Bannour et al., 2013). A tremendous amount of 
cognitive measurements are available. The tests described below are used in this thesis and 
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are included based on existing literature on well-established tests investigating cognitive 
domains associated with MDD, ASD and serotonin.  
Executive function is an umbrella term and refers to a set of complex processes of planning, 
inhibition control, decision-making, cognitive flexibility, creativity and effective 
performance (Jurado and Rosselli, 2007). These are important abilities with high impact on 
everyday life functioning, and can be assessed by using several different tests.  
The Continuous Performance Test (CPT), developed by Conners and derived from the 
original Rosvold with colleagues in 1956, initially for investigating patients with brain 
injuries (Rosvold et al., 1956). It is a popular tool, both in clinical assessment as in 
psychiatric research, and is designed to evaluate attention and vigilance/response inhibition 
of executive control. However, the performance also relies on other cognitive abilities 
including maintenance of task instructions, visual perception of stimuli and manual 
response. CPT is a computerized test, where the participant monitors a continuous 
presentation of stimuli in various time intervals with the instructions to react as fast as 
possible to the occurrence of a target. An analysis of  the performance includes fifteen 
variables, where detectability (d`) is acknowledged as the primary outcome measure.  
Another well-established and often used test is Verbal fluency. Several versions are 
available with various combinations of letters and categories, but the most commonly used 
version is perhaps the letter production task FAS (Bechtoldt et al., 1962). The instruction is 
to produce as many items starting with a certain letter (F, A, S) within one minute. The 
Verbal fluency test has later been extended with tasks also in category production and 
semantic flexibility. In the former, the participant is asked to produce as many words as 
possible for a particular category within one minute, for instance animals or fruits, and in 
the subtest semantic flexibility, the task is to switch between two categories that are not 
naturally associated with each other within one minute, such as fruits and furniture. Total 
number of correct items or switches produced within one minute in each subtest is used to 
examine abilities of attention, semantic and long-term memory, information processing 
speed as well as executive functions of initiation and strategic retrieval (Ruff et al., 1997).  
The Trailmaking test is another frequently used instrument and consists of two subtests. In 
Trailmaking test A (TMT A), the instruction is, by pen and paper or on a computer, to draw 
a line connecting numbers in chronological order. In Trailmaking test B (TMT B), the 
participant is asked to draw a line connecting alternating numbers and letters in sequence. 
Performance is assessed by the time taken to complete each test. Although both tests are 
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used to measure attention, motor speed and working memory, TMT B requires additional 
cognitive effort in cognitive flexibility and set shifting due to the instruction to alternate 
between two sets of categories (numbers and letters)(Kortte et al., 2002).  
Another common cognitive flexibility and set shifting measurement is the Wisconsin card 
sorting test (WCST), which nowadays is a computer-based test and involves sorting cards 
by different task rules, such as color, number or shape of figure based on feedback (Berg, 
1948; Grant and Berg, 1948). More specifically, the participant is required to maintain or 
shift a strategy due to positive or negative feedback given after each set and based on an 
unknown sorting rule that changes without warning. The responses are interpreted by the 
program providing fifteen outcome measures. One frequently used measure is perseverative 
errors, which is the number of failures to shift a set in response to negative feedback, where 
a high score indicates lower performance with reduced set shifting ability.  
At date, several tower tests of executive function are available, such as the Tower of 
London (Shallice, 1982), the Tower of Hanoi (Simon, 1975) and Delis-Kaplans Tower test 
(Delis et al., 2001). The tests share similar principles of planning and problem-solving 
skills, but are not completely comparable due to different instructions, task structure, 
reliability as well as that they have been suggested to measure different constructs within 
the executive function domain (Humes et al., 1997; Larochette et al., 2009). In our studies, 
D-KEFS Tower test has been used (however, named Tower of Hanoi in Study III). In this 
test, the participant is instructed to move disks of varying sizes on three pegs to a specified 
ending position in as few moves as possible. The performance is scored according the sum 
of completion times for all nine trials (Delis et al., 2001).  
Rey´s complex figure test (RCFT) was developed by Rey in 1941 for initially investigating 
brain damages in adults (Rey, 1941). It was later standardized by Osterrieth (Osterrieth, 
1944) and is nowadays used in several fields for investigating visuospatial and visuo-
constructive memory. Similar versions but with different designs have been developed for 
comparison with RCFT of pre- and post-treatment, including Taylor Complex Figure Test 
(TCFT). The traditional administration of the test uses an incidental procedure divided into 
two parts, the first one requires the participant to copy a complex geometric figure while 
viewing it, the second part requires the participant to reproduce the figure from memory 
after a time interval of, usually, 3 and 30 minutes respectively. The most well-used scoring 
system involves placement and accuracy scoring, which ranges from 0 to 36. The copy trial 
is used to assess perceptual analytic strategy and is a parameter of the visuo-constructive 
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ability, and the recall trials are used to assess the amount and the quality of information 
retained, which evaluates visuospatial memory within declarative memory. 
Social cognition is a multi-dimensional construct, which includes cognitive processes 
underlying social behavior, such as to understand and reason about others and ones’ own 
feelings, thoughts and intentions. One such aspect is the theory of mind (ToM), which 
refers to a meta-cognitive ability in understanding and attributing thoughts, beliefs and 
intentions of others (Baron-Cohen et al., 1985). In this thesis, social cognition have been 
measured by using the Movie for the assessment of social cognition, Reading the mind in 
the eyes and Faux pas. The test of Movie for the assessment of social cognition (MASC) 
was developed by Dziobek and colleagues (2006) as an alternative for assessment of ToM. 
The intention was to resemble realistic and socially high-demanding situations. MASC is a 
computerized test, showing a fifteen minutes long movie of four characters at a dinner party 
with multiple-choice questions for the participant to answer concerning thoughts, beliefs 
and intentions of the characters. Performance is scored as the sum of total correct answers, 
which ranges from 0 to 44. The Reading the mind in the eyes test is a well-established and 
nowadays computerized test measuring ToM in adults (revised version)(Baron-Cohen et al., 
2001). The instruction is to define the expressed emotion when viewing only the eye region 
displayed on a computer screen. The participant chooses one of four alternatives, and total 
sum of correct answers (total 36 items) is used as outcome variable. The Faux pas test for 
adults was developed by Stone and colleagues (Stone et al., 1998)(based on the version for 
children (Baron-Cohen et al., 1999)) and measures the ability to recognize social rule 
violations when presented with stories describing social situations and unintentionally 
social rule violations, such as that one character unintentionally makes an inappropriate 
comment resulting in negative feelings in another character. Administration of the test 
consists of reading the stories aloud to the participant while the participant is provided also 
with a written version. In total, 20 stories are presented. Ten faux pas stories are randomly 
interleaved with ten control stories without a faux pas. For each story, six questions are 
asked covering aspects of detection of a faux pas, person identification, explanation, false 
belief, empathy as well as a control question. Performance is assessed by the total score of 
60 possible points from the questions in the stories containing a faux pas.  
Central coherence refers to the ability to derive overall meaning from details (Frith and 
Happé, 1994), where strong central coherence implies a cognitive style to combine details 
into a global meaning, to use the context for an overall understanding and to switch 
between details and global strategy when necessary. Contrarily, weak central coherence 
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indicates a focus on details or local processing and failure to extract global meaning. Tests 
used to measure this cognitive ability are, among a few others, the Embedded figure test 
(EFT) and Fragmented picture test (FPT). EFT involves detection of a geometric figure 
hidden within a complex background (Witkin et al., 1971; Shah and Frith, 1993). In detail, 
the participant is presented with a complex background and asked to describe it. A 
geometric figure is then presented while the complex background is removed. Lastly, the 
complex background is again presented while the geometric figure is removed, where the 
participant is to locate the geometric figure within the complex background. Performance is 
assessed for reaction time to complete the task, with a total of twelve tasks. FPT, developed 
in 1987 (Snodgrass et al., 1987) from the original Gollin figures (Gollin, 1960), is designed 
to measure visual coherence by identification of common objects, such as pig or shoe, from 
partially completed (fragmented) pictures. Herein, the subject is presented with a picture 
that frame-by-frame forms over ten levels, and is instructed to verbally respond to what the 
picture might represents as soon as possible. If the answer is incorrect, the task continues. 
The outcome measure is the summarized reaction time to complete the, in total, ten pictures 
included in the test.  
1.5 THE SEROTONIN SYSTEM 
Serotonin (5-hydroxytryptamine, 5-HT) is a widely distributed neurotransmitter in the 
human body (Dahlström and Fuxe, 1964; Steinbusch, 1981). A majority of the serotonin is 
located in the gut (synthesized in enterochromaffin cells) regulating digestion through 
intestinal movements (Gershon and Tack, 2007), and a smaller part of serotonin can be 
found in blood platelets involved in hemostasis facilitation (Berger et al., 2009).  
Less than one percent of all serotonin in the human body is located in the brain (Hornung, 
2003). The serotonergic neurons originate from brainstem raphe nuclei, where serotonergic 
cell bodies are found, synthesizing serotonin from tryptophan, and project via axonal 
connections throughout the brain. Serotonin is essential for a wide range of functions, 
including temperature regulation, appetite, sleep, sexual behavior as well as aggression and 
cognition (Buhot, 1997; Lucki, 1998; Buhot et al., 2000).  
The serotonin system includes a transporter and several receptors regulating homeostasis in 
different ways. The serotonin transporter (5-HTT) has been intensively examined since the 
development and progress of the antidepressant drugs with selective serotonin reuptake 
inhibitor (SSRI) activity in the 1990`s. The main role of 5-HTT, located on pre-synaptic 
serotonergic neurons, is to transport released serotonin from the extracellular space back to 
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the presynaptic neuron. Regarding the serotonin receptors, fourteen subtypes have been 
identified and classified into seven families (5-HT1-5-HT7). Further, within the serotonergic 
receptor family, the 5-HT1A and 5-HT2A are perhaps the most studied serotonergic 
receptors. The interest for the 5-HT1B was initially low, partly because it was initially 
claimed to exist only in animals, and partly because of difficulties in separating 5-HT1B 
from 5-HT1D (Sari, 2004; Ruf and Bhagwagar, 2009), but the interest has since clarity in 
classification greatly increased. The 5-HT1B receptor is perhaps best known for its role in 
aggression and impulsivity, but is suggested to also be involved in drug-abuse 
reinforcement, anxiety, depression, as well as migraine. The 5-HT1B receptor is an 
inhibitory G-protein coupled receptor. High distribution of the receptor has been found in 
basal ganglia, striatum and neocortex, and lower levels have been demonstrated in the 
amygdala and hippocampus. The function of the 5-HT1B receptor depends on its location. 
The presynaptic autoreceptor on serotonergic terminals regulates serotonergic levels via a 
negative feedback system, whereas the postsynaptic heteroreceptor on other neurons is 
involved in regulation of other neurotransmitters, including dopamine, acetylcholine, 
glutamate and GABA (Chenu et al., 2005). Hence, the role of serotonin is very much 
significant and diverse, and thus not a specific effect, but more of a modulatory function 
with sophisticated interactions with other neurotransmitter systems.  
Hypotheses of the relationship between serotonin and the psychiatric disorders MDD and 
ASD have existed since 1960´s. For MDD, Schildkraut and Coppen implicated the 
involvement of serotonin in affective disorder, resulting in the monoamine hypothesis of 
depression (Schildkraut, 1965; Coppen, 1967). Other studies have demonstrated reduced 
serotonin metabolite levels in the cerebrospinal fluid of MDD patients compared to controls 
(Asberg et al., 1976), acute tryptophan depletion resulted in increased MDD symptoms in 
remitted patients (Ruhé et al., 2007) as well as positive pharmacological effects of SSRI 
targeting 5-HTT on MDD (Mace and Taylor, 2000), which also have been suggested to 
improve cognitive function in MDD patients (Rosenblat et al., 2015). Neuroimaging studies 
with positron emission tomography (PET) have shown significant differences in 5-HTT 
availability between MDD cases and controls, making a deviation in 5-HTT expression the 
most replicated molecular imaging finding in MDD (Savitz and Drevets, 2013). Findings of 
5-HT1B receptor in preclinical MDD models are inconclusive. Selective 5-HT1B knockout in 
mice has shown antidepressant-like behavior (Nautiyal et al., 2016) and overexpression of 
5-HT1B has been associated with antidepressant-like effects (McDevitt et al., 2011). In 
humans, neuroimaging research shows an involvement of 5-HT1B in psychiatry. For 
example, higher 5-HT1B binding was associated with higher levels of psychopathic traits (da 
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Cunha-Bang et al., 2016), decreased 5-HT1B binding was found in subjects with cocaine-
dependency (Matuskey et al., 2014) and decreased 5-HT1B binding was reported in PTSD 
and also associated with greater symptom severity (Murrough et al., 2011a). Molecular 
imaging literature related to MDD is very limited, but is nevertheless indicating a tendency 
of low 5-HT1B availability in patients with MDD (Murrough et al., 2011b; Tiger et al., 
2016, 2018).  
Since the discovery of elevated whole blood serotonin in a subsample of children with ASD 
(Schain and Freedman, 1961), a large number of studies have been performed investigating 
serotonin in ASD. Findings indicate central serotonin alterations in ASD, both preclinical 
observations linking serotonin deviations to autistic traits (Veenstra-VanderWeele et al., 
2012) as well as tryptophan depletion studies showing exacerbate repetitive behavior and 
unpleasant emotions in adults with autism (McDougle et al., 1996). Also, findings of 
recognition of emotion and response inhibition have been associated with serotonin level 
abnormalities in individuals with ASD (Daly et al., 2012). Neuroimaging studies of adults 
with ASD have primarily focused on 5-HTT and the serotonin receptors 5-HT1A and 5-
HT2A within the serotonin system. Studies of 5-HTT have demonstrated lower binding in 
children and adolescents with ASD (Makkonen et al., 2008) and in adults with ASD 
(Nakamura et al., 2010), which also found a positive correlation between 5-HTT binding in 
cingulate cortex and Faux pas test. Girgis et al (2011) found no significant change in 5-
HTT availability in adult participants with ASD compared to controls. For the serotonin 
receptors, disparate or lack of findings have been reported, where one study showed lower 
5-HT2A availability in subjects with ASD using single-photon emission computed 
tomography (SPECT)(Murphy et al., 2006), whereas others could not find a difference in 5-
HT2A binding using PET (Girgis et al., 2011). A recent study investigating 5-HT1A receptor 
binding, found no difference between the ASD group and the control group (Lefevre et al., 
2018). Taken together, the results are supportive of suggested serotonergic differences in 






Table 1. A short and non-exhaustive historical summary of important events due to serotonin 
  




1937 Italian scientist Ersparmer discovers Enteramine in enterochromaffin cells 
and performs the first isolation of Enteramine 
  
1948 The American scientists Page, Green and Rapport introduce serotonin 
 
1949 The molecular structure (5-HT) is reported by Rapport. In many ways, this is 
the true discovery of serotonin for now it can be truly identified and studied 
  
1950´s First antidepressive drug 
  
1952 The name of serotonin is widely accepted and Enteramine is no longer used 
 
1953 Serotonin is found in the human brain/CNS by Betty Twarog (USA), leading 
to the establishment of serotonin as a neurotransmitter 
 
1954 Suggestions about the relation between brain chemistry with serotonin and 
behavior and mental disorders are made, partly based on Hoffmann´s 
(Switzerland) discovery of the properties of LSD in 1943 
  
1965 Schildkraut (USA) suggests that affective states are the consequence of 
altered brain catecholamine levels  
Monoamine theories of 
depression 
 
1967 Coppen (U.K) implicates that serotonin is involved in depression 
  
  
1974 Hoffman and Phelps (USA) develops the PET system 
  
1977 First commercial PET examination is executed and hence, the first PET 
study is published 
  
1979 Development of radioligand binding technology with 5-HT1 and 5-HT2 
binding sites 
  
1981 5-HT1B is characterized by Pedigo and colleagues (USA) 
  
Late 1980´s The antidepressive drug SSRI (Fluoxetine) hits the market 
  
 A substantial number of PET studies are investigating potential biomarkers 







1.6 POSITRON EMISSION TOMOGRAPHY  
Positron emission tomography (PET) is a molecular imaging method for visualization and 
quantification of physiological and biochemical activity in vivo. Scientifically, PET is used 
in brain research for drug development as well as quantification of receptors, transporters 
and more recently, synapse availability in relation to psychiatric disorders.  
The principle of PET is that the injected radioligand reaches and binds the target tissue in 
the brain. At decay of radionuclide, a positron is emitted. The positron travels a short 
distance in the brain tissue where it eventually collides with an electron. Since the positron 
is the anti-particle of the electron, they convert into two oppositely directed photons and 
thus, generate a pair of gamma-rays, which is detected by the highly sensitive PET system 
surrounding the participant. During a PET examination, a large number of such 
simultaneous activities of gamma-rays are collected within a time limit and used to 
reconstruct three-dimensional images of the radioactivity distribution by calculations of 
collision occurrences and by that, identify regions of high target density. After definition of 
specific regions with MR images, and generation of time activity curves, the outcome 
measure is calculated, and PET images are created for visualization. The radioligands used 
in our four studies are [11C]MADAM binding to the 5-HTT (Halldin et al., 2005) and 
[11C]AZ10419369 binding to the 5-HT1B receptor (Andersson et al., 2011), and non-
displaceable binding potential (BPND) was used, which is a measure of radioligand binding 
in the region of interest relative to that in a reference region lacking the target.  
1.7 SUMMARY  
Within psychiatry, MDD and ASD are complex disorders with heterogeneous phenotypes 
and great variation in symptom profiles. Further, overlapping symptoms occur. Cognitive 
difficulties are evident for both disorders, where some are disorder-mutual, including 
executive dysfunction, and others may be more disorder-specific, such as that impairments 
in visuospatial ability and memory are more associated with MDD, and weak central 
coherence is primarily associated with ASD. 
Treatments focusing on core symptoms of MDD as well as related symptoms in ASD (for 
instance anxiety and sleeping problems) are available, both psychological/behavioral 
interventions and pharmacotherapy. A role for serotonin in the pathophysiology of MDD 
and ASD has been suggested, where neuroimaging studies have demonstrating deviations 
in the serotonin system, especially the serotonin transporter, for both MDD and ASD. 
However, treatment focusing on cognitive impairment is hampered due to limited 
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understanding of neurobiological aspects of cognitive functioning, why the overall aim of 
this thesis was to contribute to this limited field focusing on serotonin in relation to 





In order to contribute to the limited research field of cognitive impairment in relation to 
neurobiological markers in psychiatric disorders, the overall aim of this thesis was to 
explore associations between dimensional cognitive ability and two different markers of the 
serotonin system.  
The aim of Study I was to explore cognitive ability in depressed patients before and after 
treatment. Also, to investigate correlations between 5-HT1B binding and cognitive functions 
in patients with MDD before and after treatment and, in comparison to healthy control 
subjects.  
In Study II, we aimed to investigate cognitive ability and 5-HTT binding in an ASD group 
and, in comparison to a neurotypical control group. We hypothesized lower 5-HTT binding 
among the ASD subjects compared to the controls as well as a correlation between 
performance on the social-cognitive test of Faux pas and 5-HTT availability, as reported by 
Nakamura and colleagues (2010). A further aim was to explore putative associations 
between other relevant cognitive functions and 5-HTT binding.  
The first aim of Study III was to replicate the results from Study I, which demonstrated a 
significant correlation between visuo-constructive memory and availability of 5-HT1B 
receptors in the dorsal brainstem in the control group. The second aim was to explore other 
cognitive domains in relation to 5-HT1B availability in a larger group of healthy 
participants.  
Based on the continuous distribution of autism-like traits in the population, we aimed in 
Study IV to explore a possible link between autism-related cognitive abilities of both social 
cognition and central coherence, and markers of the serotonergic 5-HT1B and 5-HTT in a 




3 METHODS, RESULTS AND CONCLUSIONS 
3.1 STUDY I. ASSOCIATIONS BETWEEN COGNITION AND SEROTONIN 1B 
IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER – A PILOT STUDY 
3.1.1 Methods 
3.1.1.1 Participants and procedure 
In Study I, ten patients with MDD (according to diagnostic and statistical manual of mental 
disorders, DSM-IV) were recruited by advertisements in press or by the Internet Psychiatry 
unit at Psychiatry Southwest, Karolinska University Hospital, Southern Campus in 
Stockholm, Sweden. The patients were healthy according to medical history, physical 
examination with negative urine toxicology, blood analysis, had an ongoing MDD episode 
according to Mini International neuropsychiatric interview (MINI) of moderate type (score 
of 20-35 in Montgomery-Åsberg depression rating scale (MADRS)) and over the age of 18. 
The control subjects were recruited by newspaper advertisement or from a website designed 
for recruiting research participants. This group of 10 subjects had no psychiatric history and 
were otherwise healthy according to interviews with MINI or structured clinical interview 
for the diagnostic and statistical manual of mental disorders (DSM, fourth edition), and 
matched the patients in terms of gender and age (±3 years (±4 years for one pair). Exclusion 
criteria for both groups were bipolar disorder, current substance abuse, organic brain 
disorder, current psychopharmacological treatment and magnetic resonance imaging (MRI) 
abnormalities, and pregnancy.   
The procedure consisted of a magnetic resonance imaging (MRI) scan, where examinations 
with cognitive tests and PET and [11C]AZ10419369 were preferably executed on the same 
day, and within two weeks after the MRI scan. For the patient group, Internet-based 
cognitive behavioral therapy (ICBT) was initiated on the same day as the first PET 
examination (treatment duration: 11.9 ±1.4 weeks) and 14 ±2.2 weeks after treatment 
initiation, a second examination with cognitive tests and PET was performed. Also, a 
depression questionnaire was administered, both clinician-rated MADRS at each PET 
experiment (mean baseline: 26; mean follow-up: 7.4) and self-rated MADRS-S which was 
completed weekly by the patients throughout the study. The controls were examined with 
cognitive tests and PET and [11C]AZ10419369 at baseline, and only cognitive tests 
approximately twelve weeks later. The control group did not receive ICBT. Parts of the 
results have previously been published (Tiger et al., 2014, 2016).  
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3.1.1.2 Cognitive behavioral therapy  
Cognitive behavioral therapy (CBT) is a structured treatment intervention aiming to modify 
maladaptive thoughts, behaviors and emotions, and the interaction them between by 
different modules or techniques, including cognitive restructuring, behavior activation and 
exposure. Internet-based CBT (ICBT) is based on traditional CBT protocol, but is delivered 
online via a platform with digital guidance from a therapist (Hedman et al., 2012). The 
patient gets weekly access to modules and homework assignments to complete.   
3.1.1.3 Assessment of behavioral phenotypes 
Examinations of cognitive ability were executed for all participants at baseline and follow-
up. The tests were chosen based on existing literature on cognitive deficits in MDD (Blanco 
et al., 2013; Snyder, 2013; Rock et al., 2014). Hence, visuo-constructive memory ability 
was estimated by Rey complex figure test (RCFT) at baseline (Shin et al., 2006) and Taylor 
complex figure test (TCFT) at follow-up to minimize learning effects. Executive function 
was assessed with Verbal fluency subtests letter production and category production 
(Tombaugh et al., 1999) as well as Trailmaking test A and B (TMT A; TMT B) 
(Tombaugh, 2004). Also, general intellectual ability was estimated by Wechsler adult 
intelligence scale, third version (WAIS-III) subtest vocabulary.  
3.1.1.4 Image acquisition 
The MRI (Signa 1.5T or 3.0T, GE Healthcare) scan was executed for exclusion of structural 
pathology (T2-weighted images) and for co-registration with PET data (T1-weighted 
images), and later segmented into gray matter, white matter and cerebrospinal fluid using 
SPM5 (statistical parametric mapping, Wellcome Trust Centre for Neuroimaging, United 
Kingdom). The patient group was examined twice with PET (ECAT HRRT, Siemens 
Molecular Imaging) and the radioligand [11C]AZ10419369 for 5-HT1B receptor availability, 
synthesized as previously described (Pierson et al., 2008). The patient was placed 
recumbent with the head in the PET system, where a plastic helmet for minimizing head 
movements was used (Bergström et al., 1981). Brain radioactivity was measured for 93 
minutes ranging from 20 seconds to 6 minutes (mean injected radioactivity: 385.7 ±30.9 
MBq). Regions of interest were selected based on literature of deviating serotonin marker 
densities in MDD (Drevets, 2000; Savitz and Drevets, 2009; Murrough et al., 2011b); 
orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), subgenual prefrontal cortex 
(SPC), amygdala, hippocampus, ventral striatum and dorsal brainstem (DBS). The regions 
were manually defined on individual MRI images and then transferred into PET images as 
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previously described (Varnäs et al., 2011). Due to insignificant levels of 5-HT1B receptors 
(Varnäs et al., 2001), the cerebellar cortex was used as a reference region (Table 3) for 
quantification of the outcome measure of binding potential (BPND) using S-WAPI 
(stationary wavelet transform-based parametric mapping framework) implemented in 





Parametric paired samples t-tests were used for comparisons of cognitive performance from 
baseline to follow-up as well as between the matched groups. Mixed effect modeling were 
executed to investigate differences over time as this model integrates time-varying factors, 
but also takes missing values into consideration. Pearson´s correlations were applied to 
explore relationships between cognitive performance and 5-HT1B binding. For significant 
correlations from the initial analyses, a second step with multiple linear regression analyses 
at baseline were applied. Also, Pearson´s correlations were used to explore differences in 
cognitive performance in relation to differences in 5-HT1B binding in the patient group. The 
relative change in cognition and 5-HT1B binding from baseline to follow-up was calculated 
by each cognitive test and 5-HT1B binding in each brain region (cognitive performance 
follow-up – cognitive performance baseline)/cognitive performance follow-up = ∆CP; 
(BPND follow-up – BPND baseline)/BPND follow-up) = ∆BPND). 
3.1.2 Results 
The patient group was examined twice with PET, and all study subjects were examined 
twice with cognitive tests. However, due to missing data parts of the results from the 
 
Table 3. Mean [11C]AZ10419369 binding.  
 Controls BPND 
±SD 




Change in BPND 
((PET2-PET1)/PET1) 
OFC 1.08 ± 0.16 0.99 ± 0.36 0.93 ± 0.23 -0.05 ± 0.17 
ACC 1.03 ± 0.25 0.80 ± 0.27 0.81 ± 0.18 0.01 ± 0.21 
SPC 0.90 ± 0.11 0.71 ± 0.24 0.74 ± 0.19 0.05 ± 0.17 
Ventral striatum 2.03 ± 0.40 1.79 ± 0.43 1.71 ± 0.31 -0.05 ± 0.20 
Amygdala 0.91 ± 0.20 0.81 ± 0.38 0.73 ± 0.26 -0.15 ± 0.47 
Hippocampus 0.33 ± 0.12 0.26 ± 0.12 0.21 ± 0.10 -0.31 ± 0.53 
DBS 0.45 ± 0.28 0.56 ± 0.25 0.38 ± 0.20 -0.76 ± 1.02 
Note. BPND = binding potential; SD= standard deviation; PET= positron emission tomography; 




cognitive tests could not be retrieved (Table 4). No statistically significant difference 




3.1.2.1 Cognitive performance from baseline to follow-up 
The patient group showed significant improvement in verbal fluency, both letter production 
(t= –3.14; p= 0.02) and category production (t= –2.66; p= 0.038), but not in the other tests. 
The control group demonstrated a significant improvement only in verbal fluency, category 
production (t= –2.76; p= 0.04).  
3.1.2.2 Associations between cognitive performance and 5-HT1B binding  
In the patient group at baseline, moderate and positive correlations were found between 
RCFT, immediate recall (named delayed recall in the published version) and 5-HT1B 
Table 4. Results for the different subjects in RCFT/TCFT (Rey´s Complex Figure Test, Taylor´s Complex Figure Test), 
Verbal fluency letter and category production, TMT A and B (Trailmaking Test) and WAIS-III (Wechsler Adult 
Intelligence Scale, version III).  
 Controls   Patients 
 Baseline  Follow-up   Baseline  Follow-up  






















































WAIS-III  - 46.5 (9.4)
8 
  - 49.0 (6.8)
7 
 
Note. RCFT (Rey´s complex figure test) at baseline and TCFT (Taylor´s complex figure test) at follow-up; superscript= 
number of participants in each test (max=10). 
 
Table 5. Patient and matched control subject characteristics.  
Patients  Matched controls 
 Nr  Age Gender Education Hand Episodes MADRS  Age Gender Education 
1  25 Male 13 Right 2 20  29 Male 15 
2  51 Female 17 Right 10 35  54 Female 13,5 
3  46 Female 15 Right 3 28  46 Female 20 
4  68 Female 16 Right 3 24  69 Female 7 
5  66 Male 19 Right 3 28  64 Male 15 
6  37 Female 15.5 Right >10 26  36 Female 18 
7  66 Male 16.5 Right >10 25  69 Male 13 
8  24 Female 14 Right 3 26  25 Female 16 
9  57 Male 20 Right 2 24  54 Male 13 
10  38 Female 18 Right 2 24  41 Female 15 
M  47.8  16.4   26  48.7  14.6 
SD ±16.97  ±2.2   ±3.9  ±16.0  ±3.5 
Note. Education = years of education; Hand= handedness; Episodes= number of major depressive episodes; MADRS = 




binding in amygdala (rxy= 0.65; p= 0.041), ventral striatum (rxy= 0.69; p= 0.027) and DBS 
(rxy= 0.69; p= 0.028). Similar findings were shown in RCFT, delayed recall (named delayed 
recognition in the published version) and 5-HT1B binding in amygdala (rxy= 0.66; p= 0.04), 
ventral striatum (rxy= 0.71; p= 0.022) and DBS (rxy= 0.74; p= 0.015). Multiple linear 
regression analyses were performed for significant findings in the initial correlation 
analyses. However, in the patient group at baseline, no correlation survived when 
controlling for age and years of education. In the patient group at follow-up, no significant 
correlations between cognitive ability and 5-HT1B binding were found.  
In the control group at baseline, strong and positive correlations were demonstrated 
between RCFT, immediate recall (named delayed recall in the published version) and 5-
HT1B binding in the OFC (rxy= 0.89; p= 0.003) and amygdala (rxy= 0.81; p= 0.015) as well 
as between RCFT, delayed recall (named delayed recognition in the published version) and 
5-HT1B binding in the OFC (rxy= 0.96; p= 0.001) and DBS (rxy= 0.83; p= 0.021). When 
controlling for age and years of education by multiple regression analyses, the relationship 
between RCFT, delayed recall and 5-HT1B binding in DBS remained (β= 10.62; p= 0.026). 
Also, the age effect on RCFT, delayed recall was significant (β= –0.30; p= 0.013).  
3.1.2.3 Group differences in cognitive performance at baseline 
The patient group performed significantly better than the control group in RCFT, delayed 
recall (named delayed recognition in the published version)(t= 3.62; p= 0.011).  
3.1.2.4 Group differences in cognitive performance at follow-up 
The patient group performed significantly better than the control group in verbal fluency, 
letter production (t= 8.14; p= 0.001). No significant differences in general intellectual 
ability estimated with WAIS-III Vocabulary task were found.  
3.1.2.5 Effect of time and group on cognitive performance 
Significant time effects on cognitive performance in RCFT/TCFT, delayed recall (F(1, 
26)= 6.96, p= 0.014) and verbal fluency, category production (F(1, 28)= 6.11, p= 0.02) 
were found. Also, a significant group effect on cognitive performance, verbal fluency, letter 
production (F(1, 28)= 7.84, p= 0.009) was demonstrated. No significant interaction effects 
(time*group) were shown.  
 
22 
3.1.2.6 Difference in cognitive performance and 5-HT1B binding before and after 
treatment 
A relative change (∆CP and ∆BPND) was calculated to explore putative correlations 
between differences in cognition abilities and 5-HT1B binding from baseline to follow-up, 
and demonstrated significantly positive correlations between improvement in verbal 
fluency, letter production and difference in 5-HT1B binding in ventral striatum (rxy= 0.79; 
p= 0.033), between improvement in verbal fluency, category production and 5-HT1B 
binding in amygdala (rxy= 0.76; p= 0.049) as well as between improvement in TMT B and 
5-HT1B binding in DBS (rxy= 0.85; p= 0.032), amygdala (rxy= 0.87; p= 0.024) and 
hippocampus (rxy= 0.89; p= 0.017)(Table 6; Fig. 1-2).  
 
 















∆TMT A  
r (p) 
 
∆TMT B  
r (p) 
∆OFC 0.15 (0.75) 0.09 (0.84) 0.59 (0.16) 0.29 (0.52) -0.37 (0.94) 0.54 (0.27) 
∆ACC 0.26 (0.58) 0.23 (0.63) 0.55 (0.21) 0.14 (0.76) -0.50 (0.25) 0.30 (0.57) 
∆SPC -0.04 (0.94) -0.19 (0.68) -0.07 (0.89) 0.15 (0.75) -0.19 (0.68) 0.24 (0.65) 
∆VST 0.31 (0.51) 0.32 (0.49) 0.86 (0.01)* 0.29 (0.52) -0.15 (0.74) 0.24 (0.65) 
∆AMY 0.17 (0.72) 0.02 (0.96) 0.32 (0.49) 0.53 (0.22) 0.60 (0.16) 0.89 (0.02)* 
∆HIP -0.01(0.98) -0.15 (0.75) 0.10 (0.82) 0.23 (0.61) 0.18 (0.70) 0.95 (0.00)** 
∆DBS -1.01 (0.83) -0.32 (0.48) -0.02 (0.96) 0.16 (0.73) -0.14 (0.77) 0.92 (0.00)** 
Note. RCFT=Rey´s Complex Figure Test; TCFT=Taylor´s Complex Figure Test; TMT A= Trailmaking test 
A; TMT B= Trailmaking test B; ACC=anterior cingulate cortex; OFC=orbitofrontal cortex; SPC=subgenual 
prefrontal cortex; VST= ventral striatum; DBS=dorsal brainstem; AMY=amygdala; HIP=hippocampus; *= 
p<0.05; **=p<0.001.  
 
       
Fig 1. Scatter plot illustrating the association between the relative difference in letter production and binding 







































3.1.2.7 Difference in cognitive performance and clinical change before and after 
treatment 
In the patient group, no significant correlation was found between difference in cognitive 
performance (∆CP) and difference in clinical change (∆MADRS) from baseline to follow-
up.  
3.1.3 Conclusions 
The main finding showed that cognitive ability in executive function improved in depressed 
patients from baseline to follow-up, and that this improvement was associated with changes 
in 5-HT1B binding in several brain regions. Also, in the control group when controlling for 
age, a significant association was found between visuo-constructive memory and dorsal 
brainstem. In sum, these results implicate a role of the 5-HT1B receptor in cognition, both in 












Fig. 2. Scatter plot illustrating the association between relative difference in Trailmaking Test B (TMT 


































3.2 STUDY II. LOWER SEROTONIN TRANSPORTER BINDING IN ADULT 
SUBJECTS WITH HIGH-FUNCTIONING AUTISM AS MEASURED WITH 
[11C]MADAM  
3.2.1 Methods 
3.2.1.1 Participants and procedure 
Study II consisted of 15 subjects with ASD that were recruited through specialized 
healthcare clinics and 15 control subjects that were recruited by advertisement in local 
newspapers in the Stockholm region. The inclusion criteria for the ASD group were a 
clinical diagnosis of autism or Asperger syndrome according to International classification 
of diseases (ICD-10)/DSM-IV and over the age of 18. The clinical diagnosis was supported 
by the result of the Autism diagnostic observation schedule, second edition (ADOS-2), 
module 4. The control subjects did not have an ASD diagnosis and was individually 
matched to each participant with ASD based on gender (11 males, 4 females), age (±3 
years) and estimated general intellectual intelligence quotient (IQ) (±1 SD) by Wechsler 
adult intelligence scale, fourth version (WAIS-IV), subtest Matrix reasoning (Table 7). 
Exclusion criteria for all participants were current psychiatric disorder according to DSM-
IV, IQ< 70, central nervous system related disorder, psychopharmacological treatment 
within six months, nicotine use, substance abuse or other major health problems, and 
pregnancy. The sample of the present study was the same as the one described in a previous 
published article (Horder et al., 2018).  
The screening procedure contained a psychiatric interview with MINI and medical history, 
and somatic examination with blood analysis and urine toxicology, electrocardiogram as 
well as MRI. All participants were examined with cognitive tests and a PET examination 
with the radioligand [11C]MADAM for 5-HTT binding.  
3.2.1.2 Assessment of behavioral phenotypes  
All participants were assessed with an extensive cognitive test protocol. Social cognition 
was examined by Movie for assessment of social cognition (MASC)(Dziobek et al., 2006), 
Reading the mind in the eye (EYE)(Baron-Cohen et al., 2001), and Faux pas (Baron-Cohen 
et al., 1999). Executive function was assessed by using Verbal fluency, subtest letter 
production, category production and semantic flexibility, Continuous performance test-II 
(CPT) as well as the Tower test from the broader Delis-Kaplan executive function system 
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(Delis et al., 2001). Central coherence was estimated by Embedded figure test 
(EFT)(Almeida et al., 2010) and Fragmented picture test (FPT)(Snodgrass et al., 1987).  
 
3.2.1.3 Image acquisition 
An MRI scan (3T GE Discovery MR750, GE Milwaukee WI) was conducted for all 
subjects, where T1-weghted images were used for co-registration with PET data (Statistical 
parametric mapping 5 (Department of Cognitive Neurology, University College London)) 
in Matlab 2007b for Windows (MATLAB version 7.5, Natick, Massachusetts; The 
Mathworks Inc.). Regions of interest were delineated using Freesurfer software (version 
5.0, http://surfer.nmr.mgh.harvard.edu), where brain region anatomy was defined by the 
cortical atlas of Desikan-Killany (Desikan et al., 2006). During the examination, the 
Table 7. Demographics, imaging and behavioral sample characteristics.  
 ASD Control  
 n mean SD min max n mean SD min max p 
Demographic            
Age 15 33.0 9.1 19.4 48.0 15 33.1 9.4 22.1 49.1 .92 
Education (years) 15 13.7 3.4 9 20 15 16.3 4.0 11 25 .02 
WAIS matrix (sp)1 15 12.5 4.0 4 18 15 12.2 3.4 5 17 .72 
Height (cm) 15 177.3 9.6 161 189 15 179.1 8.6 167 194 .50 
Weight (kg) 15 75.8 17.0 50.6 107.7 15 73.7 12.4 51 109 .59 
Imaging            
Injected activity (MBq) 15 366.5 62.6 253 464 15 372.0 55.1 247 440 .79 
Molar activity 
(GBq/µmol) 15 228.1 85.8 73 403 15 241.3 73.6 106 373 .71 
Injected mass (µg) 15 0.54 0.34 0.24 1.36 15 0.46 0.19 0.20 0.99 .51 
Ref. Region AUC (SUV)2 15 12.1 1.96 7.8 14.4 15 11.7 1.51 10.0 15.9 .38 
Behavioral            
EYE 15 24.13 5.53 13 30 15 29.60 2.67 24 33 .005 
MASC 15 29.20 5.66 18 37 15 36.13 2.85 28 40 <.001 
Faux Pas 15 43.87 10.51 21 57 15 53.13 5.22 41 60 .005 
VF lp 15 35.13 11.40 10 52 15 49.67 15.15 24 83 .01 
VF cp 15 43.00 10.74 26 69 15 50.67 10.27 31 70 .06 
VF sf 15 12.27 3.22 4 16 15 15.87 2.97 10 20 .004 
Tower 15 519.5 275.9 205 1024 15 453.3 178.5 222 744 .56 
CPT 15 0.60 0.42 0.11 1.87 15 0.87 0.44 0.22 1.8 .06 
EFT 15 726.2 693.9 46 2353 15 468.3 198.4 151 810 .30 
FPT 15 226.3 80.4 131 394 15 213.9 93.4 80 460 .72 
Group mean and standard deviation (SD). Paired samples t-test. Reading the mind in the eye (EYE), 
Movie for assessment of social cognition (MASC), Faux pas, Verbal fluency letter production (VF 
lp), Verbal fluency category production (VF cp), Verbal fluency semantic flexibility (VF sf), Tower 
test (Tower), Conner’s continuous performance test II (CPT), Embedded figure test (EFT), 




participant was placed recumbent with the head in the PET system (ECAT Exact HR 47 
PET system (CTI/Siemens, Knoxville, TN)) while using a head fixation device for 
minimizing head movements (Bergström et al., 1981) with an acquisition time of 93 
minutes. The radioligand [11C]MADAM for 5-HTT availability was synthesized as 
previously described (Halldin et al., 2005). Brain regions were selected based on 
anatomical and functional properties of the serotonin system and putative relevance to ASD 
with a total of 20 regions including total gray matter, where cerebellar cortex was used as a 
reference region. For 5-HTT quantification, the simplified reference tissue model (SRTM) 
was used (Lammertsma and Hume, 1996).  
3.2.1.4 Statistics 
Normality of data was evaluated, which showed a normal distribution in 5-HTT binding, 
but not in cognitive performance. Hence, parametric paired samples t-tests were used for 
descriptive statistics and investigations of tracer administration, size of brain regions and 
differences in 5-HTT binding in total gray matter as well as the other 19 regions between 
the ASD group and controls. Non-parametric Wilcoxon signed-rank test was used to 
examine differences in cognitive performance between the ASD group and the control 
group. Also, non-parametric Spearman´s correlations for analyzing putative associations 
between cognitive ability and 5-HTT binding were investigated in the whole data set (n= 
30) based on the assumption that ASD represents the extreme end of a continuous 
distribution of traits rather than categorical symptoms. Corrections for multiple comparison 
were performed using the false discovery rate (FDR) method (Benjamini and Hochberg, 
1995).  
In addition, differences in 5-HTT binding between male and female sample were performed 
using paired samples t-test. Due to previous findings which demonstrated associations 
between Faux pas and 5-HTT availability (Nakamura et al., 2010), an exploratory voxel-
based analysis was executed.  
Power analysis showed that 15 subjects were required for a power of 0.8 when assuming a 
mean effect size of 0.78 (Girgis et al., 2011) and alpha value of 0.05. For outlier 
identification, Grubb´s test was used. No subject was identified as an outlier, but however, 
10 datapoints were outliers in Grubb´s test, of which 7 of these were classified as outliers 
after normalizing 5-HTT to gray matter binding according to Grubb´s test (1 in the ASD 
group; 6 in the control group). Hence, for all analyses involving 5-HTT data, outliers were 
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excluded. The statistical analyses were two-tailed and executed using R software (version 
3.4.1, R Foundation).  
3.2.2 Results 
The groups did not differ in terms of gender, age or level of intellectual ability, but the 
control subjects had significantly higher level of education (p= 0.02). No significant 
difference between the groups in imaging data of injected or molar activity, or in 
[11C]MADAM uptake in the reference region of cerebellum (Table 7).  
3.2.2.1 Assessment of behavioral phenotypes  
Non-parametric Wilcoxon signed-rank test showed that the ASD group had significantly 
lower performance in all three social-cognitive tests compared to the control group (p< 
0.005). Also, a larger variability in social-cognitive performance in the ASD group was 
observed. Moreover, the ASD group had a numerically lower performance in all executive 
functioning tests, but significant differences were found in verbal fluency, lp (n= 15, Z= 
103.5, p= 0.01) and verbal fluency, sf (n= 15, Z= 111.5, p= 0.003). In the central coherence 
tests, a numerically but not significantly, lower performance was shown in the ASD group 
for FPT (n= 15, Z= 53, p= 0.72) and EFT (n= 15, Z= 41, p= 0.30) (Table 7).  
3.2.2.2 5-HTT availability  
In total gray matter, 5-HTT binding was significantly lower in the ASD group compared to 
the control group (14.6%)(Fig. 3). 5-HTT binding was numerically lower in all nineteen 
specific brain regions in the ASD group, where 10 were significantly lower, including 
neocortex, frontal cortex, parietal cortex, rostral middle frontal, insular cortex, anterior 
cingulate cortex, posterior cingulate cortex, nucleus accumbens, and putamen (Table 8; Fig. 
4). When correcting for multiple comparisons, all findings remained significant.  
Exploration of differences in 5-HTT binding between male and female sample did not 
demonstrate gender-specific effects. The post hoc exploratory voxel-based analysis of the 
findings of Nakamura and colleagues (2010) showed two significant clusters in left 










Fig 3. 5-HTT availability in total gray matter (BPND). 
Individual values and group mean. Error bars show ± 
1 SD. Subjects with ASD and control subjects. ASD 
BPND mean [SD] 0.27 [0.05], control BPND 0.32 












































Fig 4. Mean 5-HTT availability in ASD and control group. Subjects with ASD above and 







3.2.2.3 Associations between behavioral phenotypes and 5-HTT availability  
In social cognition, Spearman´s correlation demonstrated significant and positive 
associations between all three social-cognitive tests and 5-HTT binding in nucleus 
accumbens (range in rho was 0.40 to 0.48, p< 0.034). In comparison to all 10 test variables 
presented in this study, Reading the mind in the eyes test was significantly and moderately 
correlated with the highest number of brain regions (9 regions, range in rho was 0.38 to 
0.68). MASC was positively correlated with 5-HTT binding in putamen (rho= 0.38, p= 
0.04), and Faux pas was positively correlated with 5-HTT binding in ACC (rho= 0.38, p= 
0.04) and putamen (rho= 0.38, p= 0.04).  
In executive function, significant and positive correlations were found between 5-HTT 
availability in nucleus accumbens and verbal fluency, both letter production (rho= 0.39, p= 
0.04) and category production (rho= 0.38, p= 0.05). Among the five test variables of 
executive function, the highest amount of significant correlations were found in Verbal 
fluency, semantic flexibility, which correlated positively with three regions of interest; 
Table 8. Differences in regional 5-HTT availability.  
   ASD   Control     
Region of interest n mean SD n mean SD p Difference 
Neocortex 15 0.18 0.04 15 0.22 0.05 .02* -16.4% 
Frontal cortex 15 0.16 0.04 15 0.20 0.06 .02* -19.2% 
Occipital cortex 14 0.23 0.06 14 0.26 0.06 .13 -11.2% 
Parietal cortex 15 0.19 0.04 15 0.23 0.05 .02* -16.8% 
Temporal cortex 15 0.21 0.07 15 0.24 0.06 .08 -15.7% 
Orbitofrontal cortex 13 0.20 0.08 13 0.23 0.10 .48 -11.4% 
Rostral middle frontal cx 14 0.09 0.04 14 0.12 0.05 .02* -27.4% 
Fusiform cortex 15 0.27 0.08 15 0.31 0.09 .08 -13.9% 
Insular cortex 15 0.55 0.08 15 0.62 0.11 .03* -11.7% 
Anteror cingulate cortex 15 0.37 0.06 15 0.46 0.09 .008* -19.7% 
Posterior cingulate cortex 14 0.30 0.08 14 0.36 0.08 .02* -17.1% 
Amygdala 14 1.00 0.19 14 1.02 0.18 .79 -1.8% 
Hippocampus 15 0.53 0.13 15 0.57 0.15 .46 -6.9% 
Nucleus accumbens 14 1.03 0.21 14 1.18 0.25 .03* -13.1% 
Caudate  15 0.63 0.12 15 0.71 0.11 .12 -11.4% 
Putamen 15 1.07 0.15 15 1.23 0.16 .02* -12.5% 
Pallidum 15 1.20 0.27 15 1.22 0.22 .80 -1.6% 
Thalamus 15 1.05 0.14 15 1.13 0.15 .10 -7.5% 
Brainstem 15 0.73 0.17 15 0.86 0.15 .008* -15.0% 
5-HTT availability (BPND) in 18 subregions of grey matter and brainstem. Group mean and 
standard deviation (SD). Paired samples t-test. Presented numbers are not corrected for 




rostral middle frontal cortex (rho= 0.39, p= 0.04), caudate (rho= 0.40, p= 0.03) and 
thalamus (rho= 0.48, p= 0.01). CPT correlated significantly with thalamus (rho= 0.38, p= 
0.04). No significant correlations were found between the Tower test and 5-HTT binding in 
any region.  
In central coherence, two positively significant correlations were shown between EFT and 
5-HTT binding in nucleus accumbens (rho= 0.42, p= 0.03) and insula (rho= 0.38, p= 0.04). 
No correlations were significant between FPT and 5-HTT binding (Fig. 5).   
When correcting for multiple comparisons, only the correlation between Reading the mind 







Fig 5. Correlations between 5-HTT availability and performance in behavioral phenotype assessments. 
Spearman´s correlation coefficient. GM= total gray matter; NEOC= neocortex; FC= frontal cortex; OC= 
occipital cortex; PC= parietal cortex; TC= temporal cortex; OFC= orbitofrontal cortex; rMFC= rostral middle 
frontal cortex; FFC= fusiform cortex; INS= insular cortex; ACC= anterior cingulate cortex= PCC= posterior 
cingulate cortex; AMG= amygdala; HIP= hippocampus; NAc= nucleus accumbens; CAU= caudate; PUT= 
putamen; PAL= pallidum; THA= thalamus; BS= brainstem; EYE= reading the mind in the eyes; MASC= 
movie for the assessment of social cognition; VF lp= verbal fluency, letter production; VF cp= verbal 
fluency, category production; VF sf= verbal fluency, semantic flexibility; Tower= tower test; CPT= 
continuous performance test; EFT= embedded figure test; FPT= fragmented picture test. In tests of Tower, 
EFT and FPT, a higher score is indicative of lower performance. For visualization purposes, the sign of 
Spearman´s correlation for these tests has been changed in the figure to reflect the positive relationship 
between 5-HTT availability and cognitive performance (*p< 0.005, **p< 0.01; ***p< 0.001, uncorrected for 














































































Significantly lower 5-HTT binding in total gray matter in the ASD group compared to a 
matched neurotypical group was found. Numerically lower performance in all tests in the 
ASD group was demonstrated. Also, associations were found between cognitive abilities of 
social cognition, executive function, central coherence and 5-HTT availability in several 
brain regions, however, when correcting for multiple comparisons, only the association 
between social cognition and 5-HTT availability in ACC remained significant. In addition, 
we replicated a previous correlation between social cognition and regional 5-HTT binding. 
Hence, these findings are in line with the theory of serotonin involvement in ASD 
neurodevelopment and further endorse the involvement of serotonin in the physiology and 














3.3 STUDY III. ASSOCIATIONS BETWEEN COGNITION AND SEROTONIN 
RECEPTOR 1B BINDING IN CONTROL SUBJECTS – A [11C]AZ10419369 
POSITRON EMISSION TOMOGRAPHY STUDY 
3.3.1 Methods 
3.3.1.1 Participants and procedure 
The sample of Study III is a collection of healthy subjects from previous studies at PET 
center, Karolinska Institutet, Stockholm examining cognitive ability and the 5-HT1B 
receptor with PET and the radioligand [11C]AZ10419369 at baseline (Nord et al., 2013, 
2014b; Svensson et al., in manuscript; Tiger et al., 2014, 2016). Out of 54 controls 
examined with PET, 43 subjects were included in further analyses (Table 9). The remaining 
11 participants were excluded due to no available cognitive data (10 subjects) or 
segmentation failure within the MRI image (1 subject).  
The group was healthy according to the screening procedure with psychiatric interview and 
somatic examination, negative urine toxicology and MRI was performed. The participants 
had been investigated with cognitive tests and PET and [11C]AZ10419369 for 5-HT1B 
availability. Parts of the results have previously been reported (Nord et al., 2013, 2014; 
Tiger et al., 2014, 2016; Tangen et al., 2017).  
3.3.1.2 Assessment of behavioral phenotypes 
All participants had been examined with cognitive tests selected to measure domains 
associated with serotonin and MDD. Visuo-constructive memory was assessed with Rey 
complex figure test (RCFT) on immediate recall and delayed recall. Verbal fluency and 
cognitive flexibility were examined with verbal fluency subtests letter production, category 
production and semantic flexibility. Task-switching ability, processing speed and cognitive 
flexibility were investigated with Trailmaking test A and B (TMT A; TMT B) with 
outcome measure of seconds spent to complete the task. Attention and vigilance were 
examined with Continuous performance test-II (CPT) outcome measures of detectability 
(d´), reaction time and number of omissions and commissions. Cognitive flexibility were 
assessed with Wisconsin card sorting test (WCST) with outcome measures of perseverative 
errors, total errors and reaction time to positive feedback to unambiguous correct response, 
and planning ability was examined with Tower of Hanoi with outcome measure of seconds 
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with Wechsler adult intelligence scale (WAIS, third or fourth version), subtests vocabulary 
and matrix reasoning with raw scores as outcome measure.  
3.3.1.3 Image acquisition 
All subjects underwent an initial MRI scan (3.0T, GE Healthcare), where MR images were 
segmented (SPM5, Wellcome Trust Centre for Neuroimaging, U.K) and co-registered with 
PET data. The participants were examined with PET (High Resolution Research 
Tomograph, Siemens Molecular Imaging) (Wienhard et al., 2002) and the radioligand 
[11C]AZ10419369, which was synthesized as previously described (Pierson et al., 2008). 
Due to different protocols in the original studies, radioactivity was measured in a series of 
consecutive time-frames for 63 minutes (Nord et al., 2013, 2014) or 93 minutes (Svensson 
et al., in manuscript; Tiger et al., 2014, 2016). Hence, the first 63 minutes were used for 
quantification in the present study, and data reconstruction from one study (Svensson et al., 
in manuscript) was executed to ensure matching frame definitions of all the data. Moreover, 
all PET data from the original studies were re-analyzed due to different definition methods 
of regions of interest.  
Based on literature of assumed clinical relevance and 5-HT1B distribution, relevant brain 
regions were chosen for further analyses (Ruf and Bhagwagar, 2009; Tangen et al., 2017; 
Tiger et al., 2018), including gray matter, frontal cortex (FC), orbitofrontal cortex (OFC), 
dorsolateral frontal cortex (DLFC), occipital cortex (OC), anterior cingulate cortex (ACC), 
ventral striatum, hippocampus, amygdala, thalamus, insula, limbic lobe and dorsal 
brainstem (DBS). Binding potential relative to non-displaceable binding (BPND) 
quantification was calculated using SRTM with cerebellum as reference region (Varnäs et 
al., 2001). Moreover, ventral striatum, hippocampus, amygdala and DBS were predefined 
due to noise reduction using an algorithm for wavelet-aided parametric imaging 
(WAPI)(Cselényi et al., 2006), since SRTM performs less optimal for smaller brain 
regions.  
Most brain regions were automatically defined using Freesurfer (5.0.0, 
http://surfer.nmr.mgh.harvard.edu/). However, for DBS and gray matter, definition was 
based on [11C]AZ10419369 PET template data (Veldman et al., in manuscript) or SPM 
segmentation. The cerebellar region was automatically adjusted as described elsewhere 
(Matheson et al., 2017) in order to avoid spill-over from OC, cerebrospinal fluid and 




The statistical analyses were performed in two steps; replication and exploratory. To 
replicate the finding from Study I, the replication sample (n= 38) was a subgroup of the 
exploratory sample (n= 43) but without participants included in Study I (n= 5). Tests with 
Shapiro-Wilk revealed that cognitive data did not meet the assumption of normal 
distribution, hence, non-parametric tests were used for all variables. For investigation of 
inter-regional 5-HT1B binding as well as associations between regional 5-HT1B availability 
and age and level of education, Spearman´s correlations were used. A partial Spearman´s 
correlation was executed between RCFT, delayed recall and 5-HT1B binding in DBS 
controlled for age in the control group at baseline due to the finding in Study I showing a 
significant association between the visuo-constructive memory test RCFT, delayed recall 
(named RCFT, delayed recognition in the published version) and 5-HT1B binding in DBS in 
the controls. Exploratory, investigations of possible links between cognitive ability and 5-
HT1B binding in brain regions adjusting for age effects were executed. Regression analyses 
investigating dfBeta for identifying outliers that could affect the results were performed, 
due to the skew age distribution in the present sample with 63% between 20-37 years of 
age. Also, Spearman´s correlations when not controlling for age were investigated (n= 43) 
for comparison with baseline data in Study I. All tests were two-tailed except the 
replication analysis which was one-tailed, with significance level at ≤ 0.05 and SPSS 
(version 26) for Windows was used for the statistical analyses.  
3.3.2 Results 
Inter-regional correlations in 5-HT1B availability were positive and mostly strong in all 
regions but amygdala and hippocampus. When investigating age effects, correlations were 
found with RCFT, immediate recall (rho= –0.40, p= 0.05), RCFT, delayed recall (rho= –
0.48, p= 0.02), CPT, reaction time (rho= 0.46, p= 0.01) and WCST, reaction time (rho= 
0.51, p= 0.01). Also, 5-HT1B binding in all brain regions (range in rho was –0.30 to –0.80) 
but hippocampus correlated significantly with age. Level of education was not significantly 
correlated with cognitive ability or 5-HT1B binding.  
The replication analysis (n= 38) of RCFT, delayed recall and 5-HT1B binding in DBS did 
not remain significant in this sample (rho= –0.075, p= 0.68).  
The exploratory analyses (n= 43) not controlling for age revealed positive and moderate 
correlations between RCFT, immediate recall and 5-HT1B binding in gray matter (rho= 
0.32, p= 0.05), occipital cortex (rho= 0.53, p= 0.00), limbic lobe (rho= 0.33, p= 0.04) and 
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DBS (rho= 0.35, p= 0.03) as well as between RCFT, delayed recall and 5-HT1B binding in 
gray matter (rho= 0.33, p= 0.04), occipital cortex (rho= 0.53, p= 0.00), limbic lobe (rho= 
0.32, p= 0.04) and DBS (rho= 0.36, p= 0.03). Moreover, negative and moderate 
correlations were demonstrated between CPT, reaction time and 5-HT1B binding in all brain 
regions (range in rho was –0.36 to –0.59) but hippocampus and thalamus as well as 
between TMT B and amygdala (rho= –0.38, p= 0.02), and between WCST, reaction time 
and 5-HT1B binding in all brain regions (range in rho was –0.40 to –0.64) but ventral 
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In exploratory analyses controlling for age effects, negative and moderate correlations 
remained significant between CPT, reaction time and 5-HT1B binding in total gray matter 
(rho= –0.42, p= 0.02), frontal cortex (rho= –0.39, p= 0.03), OFC (rho= –0.38, p= 0.04), 
DLFC (rho= –0.37, p= 0.04), insular cortex (rho= –0.37, p= 0.04) and limbic lobe (rho=    
–0.38, p= 0.03), as well as between WCST, reaction time at and 5-HT1B availability in 
occipital cortex (rho= –0.46, p= 0.02)(Table 11). Additional post hoc correlation analyses 
showed a strong negative correlation between CPT, reaction time and CPT, amount of 
commissions (rho= –0.79, p= 0.00) and moderate correlations between WCST, reaction 
time and WCST, total errors (rho= 0.63, p= 0.00) and perseverative errors (rho= 0.66, p= 
0.00). No statistical multivariate outlier was detected using dfBeta in regression analysis.  
3.3.3 Conclusions 
The result from Study I between visuo-constructive memory and 5-HT1B availability in the 
control group could not be replicated. Exploratory analyses showed positive associations 
between visuo-constructive memory, cognitive flexibility and 5-HT1B availability as well as 
negative associations between reaction time and 5-HT1B binding in brain regions. 
Moreover, that the faster reaction time was correlated to higher number of errors. When 
controlling for age, the negative correlations between reaction time and 5-HT1B availability 
in several brain regions remained. These findings are in line with previous research 
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3.4 STUDY IV. ASSOCIATIONS BETWEEN AUTISM-RELATED COGNITIVE 
FUNCTIONING AND REGIONAL BINDING OF 5-HTT AND 5-HT1B 
RECEPTOR IN NEUROTYPICAL CONTROL SUBJECTS 
3.4.1 Methods 
3.4.1.1 Participants and procedure 
In this study, both 5-HTT binding and 5-HT1B receptor binding were investigated in relation 
to autism-related cognitive ability, why the sample consisted of two groups. However, some 
of the subjects (n= 17) have been examined with both radioligands and thus, occur in both 
groups. In the 5-HTT group, 32 participants were examined with PET and the radioligand 
[11C]MADAM and cognitive tests. This group (15 males, 17 females) had a mean age of 
40.16 (±13.85 SD) and mean years of education of 16.10 (±4.04 SD). In the 5-HT1B group, 
33 subjects were examined with PET and the radioligand [11C]AZ10419369 and cognitive 
tests. This group with 13 males and 20 females had a mean age of 38.27 (±14.91) and mean 
years of education of 15.43 (±3.53 SD).  
Subjects were included if they were healthy according to psychiatric assessment with 
clinical interview with MINI as well as a physical examination and negative urine 
toxicology. Main exclusion criteria for participation were history of psychiatric chronic 
disorders, substance abuse, head trauma and other major health problems as well as 
contraindications for MRI, or pregnancy. A subset of the data has previously been 
published (Nord et al., 2014; Tiger et al., 2014, 2016), and some of the participants (n= 15) 
occur also in Study II.  
3.4.1.2 Assessment of behavioral phenotypes 
Tests measuring dimensional autism-related cognition were performed for all participants. 
The domain of social cognition contained the Movie for assessment of social cognition 
(MASC)(Dziobek et al., 2006), Reading the mind in the eye (Baron-Cohen et al., 2001) and 
Faux pas (Baron-Cohen et al., 1999). In central coherence, Embedded figure test (EFT) and 
Fragmented picture test (FPT)(Snodgrass et al., 1987) were included.  
3.4.1.3 Image acquisition 
All subjects were scanned with MRI (3.0T, GE Healthcare) for exclusion of structural 
pathology (T2-weighted images) and anatomical co-registration of relevant brain regions 
(T1-weighted images) as previously described using SPM5 or SPM12 (Wellcome 
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Department of Cognitive Neurology, University College, London, U.K.). In all PET 
examinations, the subject was placed recumbent with the head inside the PET system using 
a plastic fixation device for minimizing head movements (Bergström et al., 1981) injected 
with the radioligands [11C]MADAM or [11C]AZ10419369, which were synthesized as 
previously described (Halldin et al., 2005; Pierson et al., 2008).  
In the 5-HTT group (n= 32), fifteen participants were examined with PET High Resolution 
system (ECAT Exact HR 47 PET system (CTI/Siemens, Knoxville, TN)) and 
[11C]MADAM binding with an acquisition time of 93 minutes (Andersson et al., 2020). 
Freesurfer (version 5.0, http://surfer.nmr.mgh.harvard.edu)(Fischl, 2012) was used for brain 
region delineation, and a cortical atlas of Desikan-Killany was used for brain region 
anatomy definition (Desikan et al., 2006). The 5-HTT binding outcome measure of BPND 
was calculated with SRTM model (Lammertsma and Hume, 1996) with cerebellar cortex as 
reference region. The additional seventeen subjects were examined with PET High 
Resolution Research Tomograph system (ECAT HRRT PET system (Siemens Molecular 
Imaging)) and [11C]MADAM with an acquisition time of 93 minutes (Svensson et al., in 
manuscript). Freesurfer (version 6.0, http://surfer.nmr.mgh.harvard.edu)(Fischl, 2012) was 
used for brain region delineation.  The 5-HTT binding outcome measure of BPND was 
calculated with Logan reference tissue method (Logan et al., 1996) with cerebellum as 
reference region. Relevant brain region were chosen based on existing literature of autism-
related cognition and 5-HTT distribution; gray matter, frontal cortex, OFC, occipital cortex, 
parietal cortex, temporal cortex (TC), ACC, posterior cingulate cortex (PCC), 
hippocampus, amygdala, thalamus, insula, striatum, caudate, pallidum, putamen, ventral 
diencephalon (VDC), accumbens, limbic lobe and brainstem. 
In the 5-HT1B group, 33 participants were examined with PET HRRT and 
[11C]AZ10419369. Due to different PET protocols with time lengths between 63 and 93 
minutes in the original studies, the first 63 minutes were used for quantification to enable 
pooling of data. Thus, this required raw data reconstruction from one study (Svensson et al., 
in manuscript) to ensure matching frame definitions of all the data. Freesurfer (5.0, 
http://surfer.nmr.mgh.harvard.edu/)(Fischl, 2012) was used for definition of all brain 
regions but DBS and gray matter, where a [11C]AZ10419369 PET template data was used 
(Tiger et al., 2020; Veldman et al., in manuscript) or by SPM segmentation. SRTM 
(Lammertsma and Hume, 1996) was used for BPND quantification with cerebellar cortex as 
reference region as it has negligible 5-HT1B densities (Varnäs et al., 2001). The cerebellum 
was automatically adjusted as previously described (Matheson et al., 2017) to avoid spill-
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over from OC, cerebrospinal fluid and cerebellar vermis. Also, since SRTM performs better 
with bigger brain regions than smaller, ventral striatum, hippocampus, amygdala and DBS 
were predefined for noise reduction using an algorithm for wavelet-aided parametric 
imaging (WAPI)(Cselényi et al., 2006). Analyzed brain regions were gray matter, frontal 
cortex, orbitofrontal cortex (OFC), occipital cortex, dorsolateral frontal cortex (DLFC), 
anterior cingulate cortex (ACC), hippocampus, amygdala, thalamus, insula, ventral 
striatum, limbic lobe and dorsal brainstem (DBS).  
3.4.1.4 Statistics  
Descriptive statistics are presented in Table 12. In the 5-HTT group, since two different 
PET system and quantification methods were used (fifteen subjects with HR and seventeen 
subjects with HRRT) BPND values were standardized to z-scores and pooled for further 
analyses. The Shapiro-Wilk test showed that most variables and approximately half of the 
z-transformed 5-HTT data were not normal distributed, why non-parametric tests were 
applied. Non-parametric Spearman´s correlation was executed to examine inter-regional 
associations as well as associations of cognitive ability in relation to age and years of 
education and serotonin binding in relation to age and years of education, in each sample. 
Spearman´s correlation was used to examine potential associations between autism-related 
cognition and z-transformed BPND values for 5-HTT and 5-HT1B. Since significant 
associations were found between age and 5-HT1B binding, partial Spearman´s correlations 
controlling for age were performed between cognitive ability and 5-HT1B binding. No 
associations were found between age and standardized 5-HTT binding, why age was not 
corrected for in further analyses involving 5-HTT data. Moreover, because of the 
exploratory and hypothesis-driven approach of this study, the results are presented 
uncorrected for multiple comparisons, but additional corrections for multiple comparisons 
were executed using the false discovery rate method (FDR)(Benjamini and Hochberg, 
1995). The level of significance was ≤ 0.05 and all tests were two-tailed and performed 
with SPSS 26 for Windows or R software (version 3.4.1, R Foundation).  
3.4.2 Results  
Inter-regional correlations showed positive associations in both z-transformed 5-HTT and 
5-HT1B binding. In the 5-HTT group, no significant correlation was found between age and 
cognitive ability, or age and standardized 5-HTT binding in any brain region. The variable 
years of education was significantly correlated with the cognitive test EFT (rho= –0.50, p= 
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0.003) and standardized 5-HTT binding in ACC (rho= –0.37; p= 0.036) and accumbens 
(rho= –0.47; p= 0.007). In the 5-HT1B group, no significant correlation was found between  
 
 
age and cognitive ability. Correlations between age and 5-HT1B binding were significant for 
all the brain regions (range in rho: –0.36 to –0.84; p< 0.05). The variable years of education 
was significantly correlated with the cognitive test EFT (rho= –0.66, p< 0.001), but not 
with 5-HT1B binding.  
In the 5-HTT group, Spearman´s correlation demonstrated significant associations between 
the cognitive test MASC and standardized 5-HTT availability in striatum (rho= 0.37, p= 
0.042), putamen (rho= 0.49, p= 0.005) and brainstem (rho= –0.42, p= 0.02)(Table 13). 
Similar strength of the correlation in both the HR and HRRT group was demonstrated when 
analyzing them separately. In the 5-HT1B group, Spearman´s correlation not controlled for 
age, showed that EFT was significantly correlated with 5-HT1B binding in thalamus (rho= 
0.42; p= 0.02)(Table 14). However, when controlling for age, this correlation was no longer 
significant (Table 15). Additional analyses of multiple comparison in the 5-HTT group 
were executed, where no findings remained statistically significant.  
Table 12. Descriptive statistics for the sample examined with PET and [11C]MADAM  binding to 
the serotonin transporter (5-HTT) and the sample examined with PET and [11C]AZ10419369  
binding to 5-HT1B receptor 
 Serotonin transporter sample (total n= 
32) 
 5-HT1B receptor sample (total n= 33) 
 n Range M (SD)  n Range M (SD) 
MASC 32 27-42 35 (4.07)  33 25-42 34 (4.34) 
EYE 32 20-33 28 (3.30)  32 20-32 28 (3.24) 
Faux pas 32 41-60 54 (4.90)  17 46-60 55 (4.55) 
EFT 32 31-1509 473 (322.24)  33 31-1509 514 (330.44) 
FPT 32 80-460 185 (79.77)  33 87-538 197 (87.59) 
Note. MASC= movie for assessment of social cognition; EYE= reading mind in the eyes; EFT= 
embedded figure test, seconds; FPT= fragmented picture test, seconds; n= number of participants; 






The results demonstrated positive association between 5-HTT binding in striatum and 
putamen and social cognition as well as a negative correlation between 5-HTT binding in 
brainstem and social cognition in neurotypical subjects. Moreover, a positive correlation 
between 5-HT1B availability and central coherence was found, but when controlling for age 
effects, the correlation did not remain significant. The present study did not support an 
association between 5-HT1B and social cognition, but our significant findings of 5-HTT 
binding in relation to social cognition support previous literature of ASD and suggest a 
dimensional approach of neurobiological and behavioral phenotype for social functioning 




Table 13. Spearman´s correlations (rho) between performance in tests of autism-related 
cognitive functions and regional standardized 5-HTT binding (n= 32). 
 MASC EYE Faux pas EFT FPT 
Gray matter -0.22 -0.08 0.16 0.19 0.17 
Frontal cortex 0.02 0.00 0.09 0.10 0.17 
OFC 0.02 -0.06 0.04 -0.08 0.13 
Occipital cortex -0.28 -0.17 0.03 0.25 0.24 
Parietal cortex -0.31† -0.09 -0.04 0.17 0.20 
Temporal cortex -0.13 -0.05 0.13 0.22 0.23 
ACC 0.08 0.07 0.12 -0.01 0.22 
PCC -0.23 0.07 -0.11 -0.17 0.19 
Hippocampus -0.17 -0.04 0.21 0.14 0.15 
Amygdala 0.18 -0.05 0.28 0.06 -0.06 
Thalamus -0.03 -0.01 0.26 0.20 0.06 
Insula -0.07 -0.01 0.07 0.03 0.24 
Striatum 0.37* -0.06 0.14 -0.14 -0.02 
Caudate 0.11 0.07 -0.05 -0.16 0.03 
Pallidum 0.23 0.11 0.34 0.14 0.15 
Putamen 0.49** -0.04 0.26 -0.10 0.07 
VDC -0.08 -0.14 0.25 0.08 0.17 
Accumbens 0.06 -0.08 0.31† 0.23 0.11 
Limbic lobe -0.16 0.03 0.11 -0.10 0.17 
Brainstem -0.42* 0.06 0.24 0.30† 0.31† 
Note. MASC= movie for assessment of social cognition; EYE = reading mind in the eyes; 
EFT= embedded figure test; FPT= fragmented picture test; OFC = orbitofrontal cortex; 
ACC= anterior cingulate cortex; PCC= posterior cingulate cortex; VDC= ventral 









Table 14. Spearman´s correlations (rho) between performance in tests of autism-related 
cognitive functions and regional 5-HT1B binding, not controlled for age (n= 33).  
 MASC EYE Faux pas EFT FPT 
Gray matter -0.05 0.25 0.12 0.06 0.13 
Frontal cortex 0.00 0.31† 0.16 0.12 0.14 
OFC -0.04 0.24 0.10 0.03 0.17 
Occipital cortex -0.04 0.09 0.10 0.12 0.14 
DLFC 0.00 0.28 0.21 0.13 0.14 
ACC -0.06 0.28 0.22 0.17 0.12 
Hippocampus -0.26 0.30† 0.17 0.06 0.23 
Amygdala -0.11 0.19 0.22 -0.16 0.02 
Thalamus -0.16 -0.31† 0.00 0.42* -0.02 
Insula -0.08 0.28 0.16 0.13 0.16 
Ventral striatum -0.03 0.04 -0.13 0.14 -0.03 
Limbic lobe -0.05 0.25 0.25 0.08 0.10 
DBS -0.14 0.12 0.23 0.10 0.11 
Note. MASC= movie for assessment of social cognition; EYE = reading mind in the eyes; 
EFT= embedded figure test; FPT= fragmented picture test; OFC= orbitofrontal cortex; 
DLFC= dorsolateral frontal cortex; ACC= anterior cingulate cortex; DBS= dorsal 
brainstem; *= p<0.05; †=p<0.1.  
 
 
Table 15. Spearman´s correlations (rho) between performance in tests of autism-related 
cognitive functions and regional 5-HT1B binding, controlled for age (n= 33). 
  MASC EYE Faux pas EFT FPT 
Gray matter -0.17 -0.13 -0.13 0.15 0.06 
Frontal cortex 0.02 0.03 -0.04 0.13 -0.22 
OFC -0.10 -0.11 -0.18 0.02 -0.07 
Occipital cortex -0.11 -0.33 -0.25 0.13 0.06 
DLFC 0.04 -0.07 0.02 0.32 -0.11 
ACC -0.14 -0.17 0.04 0.28 -0.23 
Hippocampus -0.37 0.12 0.07 0.18 0.40 
Amygdala 0.04 -0.20 0.01 -0.23 -0.18 
Thalamus -0.34 -0.45† -0.12 0.49† 0.24 
Insula -0.16 -0.13 -0.01 0.08 -0.15 
Ventral striatum -0.12 -0.36 -0.27 0.06 0.05 
Limbic lobe -0.12 -0.11 0.04 0.12 -0.22 
DBS -0.26 -0.42 -0.03 0.23 0.18 
Note. MASC= movie for assessment of social cognition; EYE = reading mind in the eyes; 
EFT= embedded figure test; FPT= fragmented picture test; OFC= orbitofrontal cortex; 





There are some limitations that need to be addressed in relation to the studies herein 
included.  
Participants included in medical research tend to have higher education than the general 
population (Tambs et al., 2009). Hence, this is a common problem, including in our studies, 
and has been addressed by using years of education as a controlling variable in the 
analyses. In sum, high education has in our studies been shown to have none to small 
impact on the findings. Further, neuroimaging studies do in general have low power due to 
small sample in comparison to other research fields, such as psychology. In light of this, 
also in combination of an often exploratory approach with several brain regions of interest 
and other variables to consider, it is essential to take into account the risk of false positive 
findings as well as false negative findings due to underpowered studies, when interpreting 
the results.  
Based on current PET methodology, the results in this thesis cannot answer questions of 
number of available serotonergic neurons or serotoninergic level in the brain, nor if higher 
5-HT1B binding entails an up-regulation of the receptor or higher amount of 5-HT1B 
receptors per synapse or neuron. Moreover, it is also not possible to draw any conclusions 
of lower 5-HTT availability in relation to down-regulation of 5-HTT or fewer 5-HTT 
containing neurons.  
Study I suffered from cognitive data loss, a variation in time aspect for cognitive testing as 
well as that the results were not corrected for multiple comparisons. Also, some of the 
results may have been driven by age as the multiple linear regression analyses controlling 
for age implied. In sum, all conclusions should be interpreted with caution.  
In Study II, the ASD group was cautiously selected, in where the results may not be 
representable for the whole ASD population with intellectual disability and high occurrence 
of comorbidity. However, this study design has also made it possible to measure ASD-
specific phenotypes with reduced risk of confounding factors. 
In Study III, age was shown to be a possible confounding factor affecting the results with a 
skewed age distribution. The majority of the sample was in the younger section (20-37 
years of age), and moreover, in particular one young subject had unproportionally large 
impact on the analyses. However, the analyses were controlled for putative age effects and 
further, dfBeta regression analysis was performed to analyze possible influence from 
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statistical outliers, which did not identify multivariate outliers. Yet, due to unexpected and 
absent correlations between age and cognitive tests known to be influenced by age, this 
could indicate atypical characteristics in the sample. For four of the subjects, there was an 
approximately 1.5 year long time interval between PET examination and cognitive testing. 
This could have effects on the results, but in the healthy population, the decline in 5-HT1B 
availability density and cognition is expected to be minor within this time interval. Also, 
since the examinations in PET were performed during different seasons, and seasonal 
variability in binding of other serotonin markers has been shown (Matheson et al., 2015), 
such effects cannot be excluded.  
The sample in Study IV is partly identical to the control group in Study II, which may 
affect the result in this study. However, comparison analyses between the whole 5-HTT 
sample and only the HR sample did not indicate that the HR sample was driving the 
association. Also, the 5-HTT sample had been examined with two different PET systems 
(HR and HRRT), which may have influenced the results. However, a study compared high-
resolution HRRT with the lower-resolution HR with the radioligand [11C]MADAM for 5-
HTT binding and demonstrated higher binding potential values for HRRT than HR (23% 
on average), but when correcting for partial volume effect, comparisons between the two 















4.1 STUDY I. ASSOCIATIONS BETWEEN COGNITION AND SEROTONIN 1B 
IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER – A PILOT STUDY 
In the patient group, we found that improvement in executive functions of verbal fluency 
and task-switching cognitive flexibility was associated with changes in 5-HT1B availability 
in amygdala, ventral striatum and hippocampus as well as DBS. Also, cognitive 
performance in the patient group improved at follow-up, where this improvement was 
significant for verbal fluency, both letter production and category production. However, the 
control group did also improve in verbal fluency, category production, which may indicate 
a learning effect in this specific test. Moreover, the patients performed better at cognitive 
tests than the control subjects at baseline. No interaction effects of time or group were 
found, which gives reason for cautious interpretation of the results. Our finding of positive 
associations between cognitive ability and 5-HT1B binding is in line with a previous study 
examining creativity and 5-HT1B availability (Varrone et al., 2015). However, the result of 
significant associations between changes in cognition and 5-HT1B binding are partly novel.  
Available, but however limited, literature demonstrates involvement of serotonergic 5-HT1B 
binding in MDD (Murrough et al., 2011b; Tiger et al., 2014, 2016). Further, serotonin has 
also been implicated in cognitive abilities known to be affected in MDD. For instance, 
verbal fluency is associated with idea fluency or creativity, which has been reported to be 
positively related to 5-HT1B availability in total gray matter in control subjects (Varrone et 
al., 2015). Also, improvements in cognitive flexibility have been shown after successful 
MDD treatment targeting serotonin (SSRI)(Blier et al., 1990; Rosenblat et al., 2015).  
4.2 STUDY II. LOWER SEROTONIN TRANSPORTER BINDING IN ADULT 
SUBJECTS WITH HIGH-FUNCTIONING AUTISM AS MEASURED WITH 
[11C]MADAM  
The findings showed lower 5-HTT binding among the individuals with ASD. Also, several 
correlations were found between behavioral phenotypes and 5-HTT binding. After 
correcting for multiple comparisons, the positive association between social cognition and 
5-HTT availability in ACC remained.  
The hypothesis of globally lower 5-HTT binding in individuals with ASD was further 
supported, and may reflect reductions of serotonergic connections and changes in 
expressions of 5-HTT, reductions in 5-HTT expression with unchanged serotonergic 
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connections. This finding of lower 5-HTT binding in brainstem as well as cortical and 
subcortical regions in comparison to that serotonergic neuronal soma and dendrites are 
located in the raphe nucleus in the brainstem and that axons project to other areas of 
cortical and subcortical regions, may indicate functional differences in serotonergic soma, 
dendrites and axons in ASD. In light of this, these results are in line with studies 
demonstrating reductions in somatodendritic and axonal development in serotonergic 
neurons in ASD models of neurodevelopmental hyperserotonemia (Whitaker-Azmitia, 
2001), showing changes in the central serotonin system in ASD.  
We found a significant positive correlation between 5-HTT binding in ACC and the social-
cognitive test of Reading the mind in the eye. This study supports the idea that the Reading 
the mind in the eye test represent an implicit or automated form of social cognition 
developed in infancy (Baron-Cohen et al., 2001; Oniski and Baillargeon, 2005), whereas 
MASC and Faux pas have been suggested to measure a more explicit or deliberate form of 
social cognition developed later in childhood (Heyes and Frith, 2014; Happé et al., 2017). 
As ASD has been suggested to mainly be associated with implicit social cognition 
alterations (Frith, 2004), our significant finding of 5-HTT binding in Reading the mind in 
the eyes test would be expected as a biomarker of etiological significance.  
Taken together, these results implicate a role of 5-HTT in behavioral phenotypes of adult 
ASD and, encourage research to replicate as well as to further explore aspects of the 
serotonin system in ASD to obtain a more comprehensive understanding of the involvement 
of serotonin in the neurodevelopment and ASD.  
4.3 STUDY III. ASSOCIATIONS BETWEEN COGNITION AND SEROTONIN 
RECEPTOR 1B BINDING IN CONTROL SUBJECTS – A [11C]AZ10419369 
POSITRON EMISSION TOMOGRAPHY STUDY  
The results revealed negative associations between reaction time and 5-HT1B binding in 
several brain regions controlling for age. Since reaction time was negatively correlated with 
amount of errors, this could be interpreted as poorer impulse inhibition, and may indicate 
an association of 5-HT1B availability in measures of impulsivity. This finding is in line with 
the results from an earlier study reporting reduced reaction time and increased number of 
errors after administration of 5-HT1B agonists to a healthy sample of volunteers. More 
specifically, decreased reaction time and increased number of errors were observed in a 
cognitive task of complex word recognition after administration of 5-HT1B enhancing drugs 
(van der Post et al., 2002). These results suggest a connection between 5-HT1B agonists and 
 
 49 
high 5-HT1B binding and increased impulsivity. The relation between low levels of brain 
serotonin and high impulsivity and aggression is well-established (Coccaro, 1992; Duke et 
al., 2013), and emerging evidence suggests that the 5-HT1B receptor is important in 
modulation of impulsivity and aggression (Bouwknecht et al., 2001; da Cunha-Bang et al., 
2016). A study investigating a selective 5-HT1B knockout model of response inhibition 
showed that mice without 5-HT1B receptors were unable to inhibit responses, and moreover, 
that the impulsive phenotype was reversed by rescue of receptors expression in adulthood 
(Nautiyal et al., 2015).  
Our study showed an asymmetrical age distribution, where most participants were between 
30-37 years old. Even though regression analysis did not demonstrate any statistical 
multivariate outliers, age was correlated with several cognitive variables and 5-HT1B 
binding in most brain regions, and hence, age may be a confounding factor in 5-HT1B 
binding and a statistical noise variable in cognitive ability. However, when controlling for 
age effects, the association between reaction time and 5-HT1B binding in total gray matter 
and specific regions remained. This indicates a direct relationship and further supports an 
important role of -HT1B receptors in the impulsive phenotype.   
4.4 STUDY IV. ASSOCIATIONS BETWEEN AUTISM-RELATED COGNITIVE 
FUNCTIONING AND REGIONAL BINDING OF 5-HTT AND 5-HT1B 
RECEPTOR IN NEUROTYPICAL CONTROL SUBJECTS 
This study demonstrated positive associations between social-cognitive ability of MASC 
and z-transformed 5-HTT binding in striatum and putamen, as well as a negative 
correlation between MASC and z-transformed 5-HTT binding in brainstem. Nakamura and 
colleagues (2010), demonstrated that reduction in 5-HTT binding was correlated with poor 
performance in social cognition. A positive correlation between central coherence with EFT 
and 5-HT1B availability in thalamus was shown, but when correcting for age, the correlation 
was no longer significant.  
The present study contribute to the hypothesis of a role of the serotonin transporter in social 
cognition in neurotypical as continuously distributed, but not serotonin receptor 1B in 




4.5 ETHICAL CONSIDERATIONS 
All studies were approved by the Regional Ethics Committee, Stockholm and the Radiation 
Safety Committee of the Karolinska University Hospital and were performed according to 
the guidelines of the Declaration of Helsinki. All participants were examined at PET center, 
Karolinska Institutet, Stockholm, Sweden.  
There are several ethical issues to consider in clinical neuroimaging studies like these. 
Participating in a study with multilevel and highly demanding assessments is challenging. 
Depressed individuals with severe type and/or suicidality according to scores higher than 
35 and/or a score higher than four on item 10 in MADRS, were excluded from participation 
(Study I). These individuals were informed and referred to a polyclinic for further 
assessments and follow-up. Also, included patients were informed that treatment would still 
be offered if they at some point during the study refused to participate. Excluded patients 
were also offered ICBT. Individuals with ASD that were excluded during the screening 
procedure (mostly because of comorbidity) had ongoing contact with healthcare services 
and/or Habilitation, why no further contact was taken (Study II). Healthy control subjects 
were not contacted after study completion. All participants were offered individual 
feedback on their study results.  
All participants did undergo a thorough screening, MRI and PET examinations, and a 
comprehensive cognitive test procedure, where these assessments were executed twice in 
one study (Study I). Precaution had been taken in order to protect the health and rights of 
the participants, such as give both verbal and written information about the study before 
written informed consent, including the possibility to withdraw at any time from the study 
without reprisal. Moreover, all subject-related information was handled confidentially and 
according to research routine practice at Karolinska Institutet, such as that each participant 
was given a specific code which was used throughout the study for anonymity reasons and 
that data was stored in locked metal cabinets and on specific password-protected servers via 
Karolinska Institutet. The study results were exclusively presented at group level for 
integrity protection of individual participants. 
The radioactive isotope that was used (11C) for radioligand labelling decays rapidly and 
disappears from the body approximately two hours after injection. The amount of 
radioactivity that is injected during a PET examination is comparable to background 
radiation from the environment during one year in Stockholm.   
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5 FINAL CONCLUSIONS AND FUTURE DIRECTIONS 
This thesis is exploring the serotonergic markers 5-HT1B and 5-HTT in relation to cognitive 
abilities. The studies are based on adult individuals with MDD and ASD as well as subjects 
without a psychiatric disorder.  
The main findings in all four studies showed significant associations between cognitive 
ability and binding in serotonergic markers of the 5-HT1B receptor and 5-HTT in 
psychiatric samples from baseline to follow-up, in comparison to matched non-psychiatric 
samples as well as in larger control samples. More specifically, Study I demonstrated 
positively significant associations between 5-HT1B binding and cognitive performance in 
MDD patients before to after treatment as well as between 5-HT1B binding and cognitive 
performance in control subjects. Also, 5-HT1B binding in healthy controls was negatively 
correlated with reaction time, which is an inverse cognitive measure where lower scores 
represents better performance (Study III). Study II showed positive correlations between 5-
HTT binding and social-cognitive performance in ASD. In Study IV, positively significant 
associations were found between 5-HTT binding and social-cognitive performance as well 
as between 5-HT1B binding and cognitive performance in control subjects. One correlation 
was found to be negatively significant (5-HTT binding in brainstem and social-cognitive 
performance).  
The conclusions drawn from our studies are to some extent in line with previous research, 
but to note, existing literature of serotonergic markers in relation to cognitive ability in 
psychiatric disorders is inconclusive. For instance, animal studies have shown better 
learning performance in complex cognitive tasks in 5-HT1B knockout mice compared to a 
control group (Wolff et al., 2003) as well as antidepressant-like effects when 
overexpressing the 5-HT1B autoreceptor (McDevitt et al., 2011). An antidepressant-like 
effects was also demonstrated in another study when stimulating the receptor with a 5-HT1B 
agonist (Chenu et al., 2008), whereas the opposite result have been found where the same 
agonist caused impaired performance in contextual memory but improved performance 
when inhibiting 5-HT1B receptors (Eriksson et al., 2008). In healthy humans, studies have 
shown positive associations between 5-HTT binding and intellectual ability when 
controlled for age and gender (Tseng et al., 2015), between 5-HTT binding and memory, 
cognitive flexibility and logical reasoning (Madsen et al., 2011) as well as between 5-HT1B 
binding and creative ability (Varrone et al., 2015) and between 5-HT1A receptor binding 
and verbal memory (Penttilä et al., 2016). Whereas other have demonstrated negative 
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correlations between 5-HT1A binding and memory (Yasuno et al., 2003), between 5-HT1B 
binding and impulsivity (van der Post et al., 2002) or lack of association between 5-HT1A 
availability and cognitive ability (Borg et al., 2006, 2009). Psychiatric research 
investigating 5-HTT have shown reduced 5-HTT availability in OCD (Reimold et al., 
2007), ASD (Nakamura et al., 2010) and in MDD (Selvaraj et al., 2011; Gryglewski et al., 
2014) with comorbid anxiety (Reimold et al., 2008), but also increased 5-HTT binding in 
MDD (Ichimiya et al., 2002; Reivich et al., 2004) and lack of association in MDD (Meyer 
et al., 2004) and ASD (Girgis et al., 2011) when compared to a control group. The role of 5-
HT1B in psychiatric disorders is less well studied, but literature has demonstrated decreased 
5-HT1B binding in MDD (Murrough et al., 2011b; Tiger et al., 2016), posttraumatic stress 
(Murrough et al., 2011a) and substance-dependency (Matuskey et al., 2014) compared to 
control subjects. Also, a positive correlation between 5-HT1B receptor binding and anger 
and psychopathy in violent offenders as well as reduction of 5-HT1B binding after treatment 
for MDD (Tiger et al., 2014). In sum, most studies implicate an involvement of serotonin in 
cognitive and psychiatric aspects, but how such associations looks like, whether it is good 
or bad to have high or low amounts of 5-HT1B receptors and 5-HTT, are not completely 
understood.   
Well-established findings are, however, the occurrence of cognitive impairments in 
psychiatric disorders. Impairments of similar cognitive domains seem to occur in several 
disorders, suggesting an overlapping cognitive phenotype within the psychiatric field, 
varying in the population with clinical phenotypes in the more extreme ends of the 
continuum. It is suggested that cognitive impairment might serve as a transdiagnostic 
phenotype across psychiatric disorders (McIntyre et al., 2019), and thus, representing an 
overlapping and dimensional approach varying along a spectrum in the population. The 
clinical neuroscientific research field is in great need of studies exploring neurobiological 
markers in relation to cognitive impairment in the psychiatric context. Pharmacological 
interventions targeting serotonin has been widely used in treating clinical symptoms, but 
are still lacking in effect on cognitive impairment, both during an active psychiatric episode 
as well as residual symptoms after clinical remission. 
Overall, the results support existing literature that cognitive deficits may serve as 
overlapping transdiagnostic phenotypes within the psychiatric field, varying in the 
population with clinical phenotypes in the more extreme ends of the continuum. 
Consequently, our findings highlight and emphasize the importance of further exploration 
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of serotonergic markers involved in behavioral phenotypes in relation to psychiatric 
disorders.  
Hence, future directions are needed and herein suggested. Firstly, the discussion of pros and 
cons with current diagnostic systems in psychiatry could be a thesis of its own. However, 
the use of only categorical symptom cut-offs hampers scientific progress due to significant 
symptom overlap between psychiatric disorders (e.g. MDD and generalized anxiety 
disorder) and diagnosis heterogeneity (Fried and Nesse, 2014), leading to uncertain results 
with confounding factors and possible noise. Instead, moving towards a more dimensional-
based approach focusing on aspects of behavioral and neurobiological phenotypes can be 
helpful (McIntyre et al., 2019). Second, the importance of multi-center studies have been 
highlighted in many previously published studies and theses. Hence, for an important 
reason – to overcome the problem with low power due to not big enough sample sizes, and 
continue the development of existing as well as discovery of new neurobiological targets 
(which has somewhat lagged since the breakthrough of SSRI). Third, scientifical studies in 
general and neuroimaging studies in particular, have become more complex in its nature 
making it difficult to replicate previous findings (Nørgaard et al., 2019). Transparency 
through pre-registration and sharing data through, for example, supplementary material, 
protect against publication bias and may encourage further replication studies and meta-
analyses. Fourth, variability in methodology has likely contributed to disparate findings, 
which further limits generalizability. A greater consensus in terms of method, protocol, 
variable measurements, assessment of behavioral phenotypes and outcome variables is 
required. In sum, a large number of different factors exist that may hamper the development 












Research is the result of systematic hard work as well as good teamwork. In this particular 
case, a large group of people have been involved in order to make this thesis possible. I 
have been very fortunate to have such knowledgeable and driven people around me, 
including engaging research participants and colleagues as well as wonderfully supportive 
friends and family. This part is a contribution to you.  
First of all, my principal supervisor, Jacqueline Borg, as much a natural force of pragmatic 
enthusiasm as a hard-working night-bird. Your straightforward supervision and inspiring 
dedication for the research field, always with up-to-date knowledge in neuroscience, have 
generated numerous food for thoughts. It has occasionally led to sleepless nights, but the 
curve of learning has been steep.  
I want to thank my co-supervisor Johan Lundberg, always with one foot in the poly-clinical 
domain, for reminding me of the psychiatric perspective when trying to disentangle 
complicated neurobiological relationships. Your scientifical expertise and ability to explain 
complex medical terms and multidimensional relationships in a comprehensible way have 
been very appreciated.  
I am very grateful to Katarina Varnäs, my co-supervisor, for bringing a neurochemical and 
PET-technical perspective as well as statistical guidance. Also, for much needed structure 
and thorough revisions with sharp eyes, where your superb sense for details during our 
manuscript writing discussions has been highly appreciated. Thank you for always taking 
the time to answer questions, such as microdialysis, G-coupled proteins or differences in 
the serotonergic receptor family, with fast response. 
I am deeply grateful to Brjánn Ljótsson, who in a sense have been with me all the way since 
university studies. First as a very engaged teacher at Karolinska Institutet and later on, as 
my PhD mentor. You have bringing me great comfort, trustworthy advice and clarity during 
occasionally hard PhD times.  
I am forever grateful to Kimmo Sorjonen, the statistical expert. Oh Lord, I do not know 





I am so thankful for my awesome lunch companions and passionate PET Talk buddies with 
Jonas Svensson, Max Andersson, Vera Kerstens, Emma Veldman, Patrik Fazio, Martin 
Gärde, Gina Griffioen, Granville Matheson, Pontus Plavén-Sigray, Anton Forsberg Morén, 
Joachim Brumberg, Maria Lee and Tove Freiburghaus. You have made the PhD years so 
much more fun.  
A special thanks to Mikael Tiger for (together with Jacqueline) introduced me into the 
exciting field of clinical neuroscience during my master thesis writing a couple of years ago 
and for being a great inspiration as well as a highly appreciated colleague.  
A great thanks to Johan Ulin, Youssef EL Khoury and Mikhail “Mike” Kondrashov for 
letting me join both radioligand synthesis and PET examinations as well as taking time to 
answer simple-for-you-but-complex-for-me chemistry-related questions and for making this 
extremely complicated field more comprehensible.  
Thanks to amazing former and present colleagues at PET center with Lars Farde, Christer 
Halldin, Nina Knave, Karin Zahir, Somsri Srilachai, Opokua Britton-Cavaco, Malena 
Kjellén, Andrea Varrone, Urban Hansson, Patrizia Miranda-Azpiazu, Zsolt Sarnyai, Patrik 
Mattson, Bogdan Mitran, Martin Schain, Karin Collste, Carl-Johan Ekman, Miklós Toth, 
Lenke Tari, Jenny Häggkvist, Rouslan Sitnikov, Göran Rosenqvist, Per Stenkrona, Kristofer 
Nyström, Simon Cervenka, Magnus Schou, Marie Svedberg, Hillevi Andersson-Sand, 
Magdalena Nord, Rafael Maior, Jonas Ahlgren, Sangram Nag, Arsalan Amir, Anne 
Byström, Zsolt Cselényi, Prodip Datta, Ali Ekhtiari, Cedrique Eteti, Anton Lindberg, Siv 
Eriksson, Mélodie Ferrat, Björn Gustavsson, Balazs Gulyas, Mahabuba Jahan, Kaisa 
Horkka, Zhisheng Jia, Guennadi Jogolev, Peter Johnström, Aurelija Jucaite, Yaser Khani, 
Denice Kidd, Rebecca Kopsch, Ryosuke Arakawa, Piotr Ochniewicz, Reza Mohammadi,, 
Vladimir Stepanov, Akihiro Takano, Pauliina Victorsson, Julio Gabriel, Camilla 
Gustafsson, Karin Olsson, Matteo Ferrante, Carsten Steiger, Zhisheng Jia, Kai-Chun Yang, 
Maria Johansson, Nadja Hellsing, Marcello Venzi, Sara Lundqvist, Susanna Nevala, and 
Åsa Södergren. Also, thank you to those whom I inevitably have missed.  
I want to thank my wonderful poly-clinical managers Hanna Duke and Åsa Gloveus for 
believing in me, for enabling this PhD with part-time work and for always having a half-
glass-full and problem-solving state of mind. Also, my fantastic co-workers, both at 
Mottagningen för ångestsjukdomar och personlighetssyndrom, St Eriksplan (Norra 
Stockholms Psykiatri), Kronans allmänpsykiatriska mottagning (Psykiatri Nordväst) as well 
as Centrum för Psykiatriforskning (CPF), Center of Neurodevelopmental Disorders at 
 
56 
Karolinska Institutet (KIND) and Internetpsykiatrienheten (Psykiatri Sydväst) with Nils 
Lindefors, Cecilia Svanborg and colleagues.  
I wish to express my gratitude to my outstanding PhD classmates from the National 
Research school in Psychiatry and Cusanus afterwork happenings with Jenny Åström, 
Johan Königsson, Hanna Björlin Avdic, Johanna Salberg, Cecilia Månsson, Hannah 
Bergman, Kristina Bondjers, Hillevi Bergvall, Mikaela Syk, Moa Bråthén Wijana, Stefan 
Nasir, Iman Alaie, Elin Thornblom and Efthymios Koup. Also, to all enthusiastic and 
inspiring teachers during the research school with Kristoffer Månsson, Nitya Jayaram-
Lindström and Katarzyna Kumanowska, to mention a few.  
Thanks to all of my fantastic friends – the source of joy and fun. You know who you are.  
Finally, my beloved family. Thank you for staying put during my mental breakdowns 
which have exponentially increased as dissertation time has approached. To Wilma and 
Andreas, for challenging me and for accepting my sometimes too ambitious workload, but 
foremost for reminding me of the world outside of research. To Karin and Tommy, for 
being so thoughtful and for always being at hand when the every-day-puzzle does not add 
up. To Sebastian, Josefine and Hanna, for being my very own cheerleading squad scattered 
all over the world, but regularly reunited for digital pep talks or nerdy pictures. To Gerd 
and Geir, for never-ending support, structure and wisdom, and for always taking my side 
without a blink of hesitation. To my family, I do not think I can thank you enough and I 













Ahern E, Semkovska M (2017) Cognitive functioning in the first-episode of major 
depressive disorder: A systematic review and meta-analysis. Neuropsychology 31:52–
72. 
Almeida RA, Dickinson JE, Maybery MT, Badcock JC, Badcock DR (2010) A new step 
towards understanding Embedded Figures Test performance in the autism spectrum: 
the radial frequency search task. Neuropsychologia 48:374–381 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19786040 [Accessed July 21, 2016]. 
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental 
Disorders (4th edition)(DSM-IV). Washington, DC. 
Andersson JD, Pierson ME, Finnema SJ, Gulyás B, Heys R, Elmore CS, Farde L, Halldin C 
(2011) Development of a PET radioligand for the central 5-HT1B receptor: 
Radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled 
compounds. Nucl Med Biol 38:261–272 Available at: https://pubmed-ncbi-nlm-nih-
gov.proxy.kib.ki.se/21315282/ [Accessed November 7, 2020]. 
Andersson M, Tangen Ä, Farde L, Bölte S, Halldin C, Borg J, Lundberg J (2020) Serotonin 
transporter availability in adults with autism—a positron emission tomography study. 
Mol Psychiatry:1–12 Available at: http://www.nature.com/articles/s41380-020-00868-
3 [Accessed August 30, 2020]. 
Asberg M, Thorén P, Träskman L, Bertilsson L, Ringberger V (1976) “Serotonin 
depression”--a biochemical subgroup within the affective disorders? Science 191:478–
480. 
Bailer UF, Frank GK, Henry SE, Price JC, Meltzer CC, Mathis CA, Wagner A, Thornton 
L, Hoge J, Ziolko SK, Becker CR, McConaha CW, Kaye WH (2007) Exaggerated 5-
HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia 
Nervosa. Biol Psychiatry 61:1090–1099 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17241616 [Accessed November 15, 2019]. 
Bannour A, Mtiraoui A, Brahem A, Ben Romdhane A, Ben Nasr S EY and BHAB (2013) 
Neuropsychological Performance in Remitted Major Depressive Disorder Patients: A 




abstract.php?abstract_id=17478 [Accessed May 29, 2016]. 
Baron-Cohen S, Leslie AM, Frith U (1985) Does the autistic child have a “theory of mind”? 
Cognition 21:37–46 Available at: http://www.ncbi.nlm.nih.gov/pubmed/2934210 
[Accessed April 29, 2018]. 
Baron-Cohen S, O’Riordan M, Stone V, Jones R, Plaisted K (1999) Recognition of faux 
pas by normally developing children and children with Asperger syndrome or high-
functioning autism. J Autism Dev Disord 29:407–418 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10587887 [Accessed April 1, 2016]. 
Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I (2001) The “Reading the Mind in 
the Eyes” Test revised version: a study with normal adults, and adults with Asperger 
syndrome or high-functioning autism. J Child Psychol Psychiatry 42:241–251 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11280420 [Accessed April 29, 
2018]. 
Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG (2015) The 
epidemiology and global burden of autism spectrum disorders. Psychol Med 45:601–
613 Available at: http://www.ncbi.nlm.nih.gov/pubmed/25108395 [Accessed May 6, 
2018]. 
Beautrais AL, Joyce PR, Mulder RT, Fergusson DM, Deavoll BJ, Nightingale SK (1996) 
Prevalence and comorbidity of mental disorders in persons making serious suicide 
attempts: A case-control study. Am J Psychiatry 153:1009–1014 Available at: 
https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/8678168/ [Accessed November 12, 
2020]. 
Bechtoldt HP, Benton AL, Fogel ML (1962) An application of factor analysis in 
neuropsychology. Psychol Rec 12:147–156 Available at: https://link-springer-
com.proxy.kib.ki.se/article/10.1007/BF03393452 [Accessed November 10, 2020]. 
Behnken A, Schöning S, Gerss J, Konrad C, de Jong-Meyer R, Zwanzger P, Arolt V (2010) 
Persistent non-verbal memory impairment in remitted major depression - caused by 
encoding deficits? J Affect Disord 122:144–148 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19692126 [Accessed April 14, 2014]. 
Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. J R Stat Soc Ser B 57:289–300. 
 
 59 
Bennabi D, Haffen E, Van Waes V (2019) Vortioxetine for Cognitive Enhancement in 
Major Depression: From Animal Models to Clinical Research. Front Psychiatry 
10:771 Available at: http://www.ncbi.nlm.nih.gov/pubmed/31780961 [Accessed 
January 30, 2020]. 
Berg EA (1948) A simple objective technique for measuring flexibility in thinking. J Gen 
Psychol 39:15–22 Available at: http://www.ncbi.nlm.nih.gov/pubmed/18889466 
[Accessed February 13, 2020]. 
Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 
60:355–366 Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/19630576/ 
[Accessed November 5, 2020]. 
Bergström M, Boëthius J, Eriksson L, Greitz T, Ribbe T, Widén L (1981) Head fixation 
device for reproducible position alignment in transmission CT and positron emission 
tomography. J Comput Assist Tomogr 5:136–141 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/6972391 [Accessed January 28, 2016]. 
Blanco NJ, Otto AR, Maddox WT, Beevers CG, Love BC (2013) The influence of 
depression symptoms on exploratory decision-making. Cognition 129:563–568 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3809321&tool=pmcentrez
&rendertype=abstract [Accessed April 21, 2014]. 
Blier P, de Montigny C, Chaput Y (1990) A role for the serotonin system in the mechanism 
of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 51 
Suppl:14–20 Available at: http://www.ncbi.nlm.nih.gov/pubmed/2157700 [Accessed 
October 28, 2016]. 
Bora E, Harrison BJ, Yücel M, Pantelis C (2013) Cognitive impairment in euthymic major 
depressive disorder: a meta-analysis. Psychol Med 43:2017–2026 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23098294 [Accessed August 11, 2017]. 
Borg J, Andrée B, Lundberg J, Halldin C, Farde L (2006) Search for correlations between 
serotonin 5-HT1A receptor expression and cognitive functions - A strategy in 
translational psychopharmacology. Psychopharmacology (Berl) 185:389–394 
Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/16541245/ [Accessed 
October 19, 2020]. 
 
60 
Borg J, Henningsson S, Saijo T, Inoue M, Bah J, Westberg L, Lundberg J, Jovanovic H, 
Andrée B, Nordstrom A-L, Halldin C, Eriksson E, Farde L (2009) Serotonin 
transporter genotype is associated with cognitive performance but not regional 5-
HT1A receptor binding in humans. Int J Neuropsychopharmacol 12:783 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19126263 [Accessed May 18, 2018]. 
Bouwknecht JA, Hijzen TH, Van der Gugten J, Maes RAA, Hen R, Olivier B (2001) 
Absence of 5-HT1B receptors is associated with impaired impulse control in male 5-
HT1B knockout mice. Biol Psychiatry 49:557–568 Available at: https://pubmed-ncbi-
nlm-nih-gov.proxy.kib.ki.se/11297712/ [Accessed October 18, 2020]. 
Buhot M-C (1997) Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 7:243–
254 Available at: 
http://www.sciencedirect.com/science/article/pii/S095943889780013X [Accessed 
December 10, 2014]. 
Buhot MC, Martin S, Segu L (2000) Role of serotonin in memory impairment. Ann Med 
32:210–221 Available at: http://www.ncbi.nlm.nih.gov/pubmed/10821328 [Accessed 
May 9, 2016]. 
Carton AM, Smith AD (2014) Assessing the relationship between eating disorder 
psychopathology and autistic traits in a non-clinical adult population. Eat Weight 
Disord 19:285–293 Available at: https://link.springer.com/article/10.1007/s40519-
013-0086-z [Accessed November 6, 2020]. 
Chenu F, Dailly E, Bourin M (2005) 5-HT1B receptor: a target for antidepressant drugs? 
Drug Dev Res 65:141–146 Available at: http://doi.wiley.com/10.1002/ddr.20017 
[Accessed November 5, 2020]. 
Chenu F, David DJP, Leroux-Nicollet I, Le Maître E, Gardier AM, Bourin M (2008) 
Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice 
with an alteration of the serotonergic system. J Psychiatry Neurosci 33:541–550 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2575758&tool=pmcentrez
&rendertype=abstract [Accessed September 23, 2015]. 
Coccaro EF (1992) Impulsive aggression and central serotonergic system function in 
humans: An example of a dimensional brain-behavior relationship. Int Clin 
Psychopharmacol 7:3–12 Available at: https://pubmed-ncbi-nlm-nih-
 
 61 
gov.proxy.kib.ki.se/1624755/ [Accessed October 19, 2020]. 
Collins PY et al. (2011) Grand challenges in global mental health. Nature 475:27–30 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3173804&tool=pmcentrez
&rendertype=abstract [Accessed April 6, 2014]. 
Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113:1237–1264 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/4169954 [Accessed April 1, 2016]. 
Cselényi Z, Olsson H, Halldin C, Gulyás B, Farde L (2006) A comparison of recent 
parametric neuroreceptor mapping approaches based on measurements with the high 
affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635. Neuroimage 
32:1690–1708 Available at: http://www.ncbi.nlm.nih.gov/pubmed/16859930 
[Accessed September 23, 2015]. 
da Cunha-Bang S, Hjordt LV, Perfalk E, Beliveau V, Bock C, Lehel S, Thomsen C, Sestoft 
D, Svarer C, Knudsen GM (2016) Serotonin 1B receptor binding is associated with 
trait anger and level of psychopathy in violent offenders. Biol Psychiatry Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/27108021 [Accessed July 8, 2016]. 
Dahlström A, Fuxe K (1964) A Method for the Demonstration of Monoamine-Containing 
Nerve Fibres in the Central Nervous System. Acta Physiol Scand 60:293–294 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/14131843 [Accessed November 
22, 2019]. 
Daly EM, Deeley Q, Ecker C, Craig M, Hallahan B, Murphy C, Johnston P, Spain D, 
Gillan N, Brammer M, Giampietro V, Lamar M, Page L, Toal F, Cleare A, Surguladze 
S, Murphy DGM (2012) Serotonin and the Neural Processing of Facial Emotions in 
Adults With Autism. Arch Gen Psychiatry 69:1003–1013 Available at: 
http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archgenpsychiatry.2012.5
13 [Accessed April 27, 2018]. 
Delis DC, Kaplan E, Kramer JH (2001) Delis-Kaplan Executive Function System: 
Technical manual. San Antonio, TX: The Psychological Corporation. 
Demetriou EA, Lampit A, Quintana DS, Naismith SL, Song YJC, Pye JE, Hickie I, 
Guastella AJ (2018) Autism spectrum disorders: A meta-analysis of executive 
function. Mol Psychiatry 23:1198–1204 Available at: https://pubmed-ncbi-nlm-nih-
 
62 
gov.proxy.kib.ki.se/28439105/ [Accessed November 9, 2020]. 
Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale 
AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ (2006) An automated labeling 
system for subdividing the human cerebral cortex on MRI scans into gyral based 
regions of interest. Neuroimage 31:968–980 Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S1053811906000437 [Accessed November 
7, 2017]. 
Drevets WC (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813–829 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11063977 [Accessed March 23, 
2014]. 
Duke AA, Bègue L, Bell R, Eisenlohr-Moul T (2013) Revisiting the serotonin-aggression 
relation in humans: A meta-analysis. Psychol Bull 139:1148–1172 Available at: 
https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/23379963/ [Accessed October 19, 
2020]. 
Dziobek I, Fleck S, Kalbe E, Rogers K, Hassenstab J, Brand M, Kessler J, Woike JK, Wolf 
OT, Convit A (2006) Introducing MASC: a movie for the assessment of social 
cognition. J Autism Dev Disord 36:623–636 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16755332 [Accessed May 27, 2014]. 
Eriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningsson P, Ögren SO (2008) 
Blockade of 5-HT1B receptors facilitates contextual aversive learning in mice by 
disinhibition of cholinergic and glutamatergic neurotransmission. Neuropharmacology 
54:1041–1050 Available at: 
https://linkinghub.elsevier.com/retrieve/pii/S0028390808000488 [Accessed December 
3, 2019]. 
Fischl B (2012) FreeSurfer. Neuroimage 62:774–781 Available at: https://pubmed-ncbi-
nlm-nih-gov.proxy.kib.ki.se/22248573/ [Accessed September 20, 2020]. 
Fossati P, Guillaume B, Ergis AM, Allilaire JF (2003) Qualitative analysis of verbal 
fluency in depression. Psychiatry Res 117:17–24. 
Fried EI, Nesse RM (2014) Depression is not a consistent syndrome: An investigation of 






[Accessed December 21, 2017]. 
Fried R, Joshi G, Bhide P, Pope A, Galdo M, Koster A, Chan J, Faraone S V., Biederman J 
(2016) A study of the neuropsychological correlates in adults with high functioning 
autism spectrum disorders. Acta Neuropsychiatr 28:286–295 Available at: 
/core/journals/acta-neuropsychiatrica/article/study-of-the-neuropsychological-
correlates-in-adults-with-high-functioning-autism-spectrum-
disorders/0EFB37AFFCC10326F9E2754A139BBDBB [Accessed November 14, 
2020]. 
Frith CD, Corcoran R (1996) Exploring “theory of mind” in people with schizophrenia. 
Psychol Med 26:521–530 Available at: https://pubmed-ncbi-nlm-nih-
gov.proxy.kib.ki.se/8733211/ [Accessed September 29, 2020]. 
Frith U (2004) Emanuel Miller lecture: Confusions and controversies about Asperger 
syndrome. J Child Psychol Psychiatry Allied Discip 45:672–686 Available at: 
https://acamh.onlinelibrary.wiley.com/doi/full/10.1111/j.1469-7610.2004.00262.x 
[Accessed November 1, 2020]. 
Frith U, Happé F (1994) Autism: beyond “theory of mind”. Cognition 50:115–132 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/8039356 [Accessed August 5, 
2016]. 
Gershon MD, Tack J (2007) The Serotonin Signaling System: From Basic Understanding 
To Drug Development for Functional GI Disorders. Gastroenterology 132:397–414 
Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/17241888/ [Accessed 
November 5, 2020]. 
Girgis RR, Slifstein M, Xu X, Frankle WG, Anagnostou E, Wasserman S, Pepa L, 
Kolevzon A, Abi-Dargham A, Laruelle M, Hollander E (2011) The 5-HT(2A) receptor 
and serotonin transporter in Asperger’s disorder: A PET study with [11C]MDL 100907 
and [11C]DASB. Psychiatry Res 194:230–234 Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0925492711001508 [Accessed May 9, 
2018]. 
Gollin ES (1960) Developmental Studies of Visual Recognition of Incomplete Objects. 
Percept Mot Skills 11:289–298 Available at: 
 
64 
http://journals.sagepub.com/doi/10.2466/pms.1960.11.3.289 [Accessed August 27, 
2020]. 
Goueli T, Nasreldin M, Madbouly N, Dziobek I, Farouk M (2019) Social cognition in 
adolescent females with borderline personality traits. Psychol Psychother Theory, Res 
Pract Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/31692159/ 
[Accessed August 25, 2020]. 
Grant DA, Berg E (1948) A behavioral analysis of degree of reinforcement and ease of 
shifting to new responses in a Weigl-type card-sorting problem. J Exp Psychol 
38:404–411. 
Gryglewski G, Lanzenberger R, Kranz GS, Cumming P (2014) Meta-analysis of molecular 
imaging of serotonin transporters in major depression. J Cereb Blood Flow Metab 
34:1096–1103 Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4083395&tool=pmcentrez
&rendertype=abstract [Accessed October 2, 2015]. 
Halldin C, Lundberg J, Sóvágó J, Gulyás B, Guilloteau D, Vercouillie J, Emond P, Chalon 
S, Tarkiainen J, Hiltunen J, Farde L (2005) [11C]MADAM, a new serotonin 
transporter radioligand characterized in the monkey brain by PET. Synapse 58:173–
183 Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/16138320/ 
[Accessed September 20, 2020]. 
Happé F, Cook JL, Bird G (2017) The Structure of Social Cognition: In(ter)dependence of 
Sociocognitive Processes. Annu Rev Psychol 68:243–267 Available at: 
https://www.annualreviews.org/doi/abs/10.1146/annurev-psych-010416-044046 
[Accessed November 1, 2020]. 
Hedman E, Ljótsson B, Lindefors N (2012) Cognitive behavior therapy via the Internet: a 
systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev 
Pharmacoecon Outcomes Res 12:745–764 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23252357. 
Heyes CM, Frith CD (2014) The cultural evolution of mind reading. Science (80- ) 
344:1357–1363 Available at: 
https://www.sciencemag.org/lookup/doi/10.1126/science.1243091 [Accessed 
November 1, 2020]. 
 
 65 
Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A (2012) The Efficacy of Cognitive 
Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res 36:427–440 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3584580&tool=pmcentrez
&rendertype=abstract [Accessed March 21, 2014]. 
Hofvander B, Delorme R, Chaste P, Nydén A, Wentz E, Ståhlberg O, Herbrecht E, Stopin 
A, Anckarsäter H, Gillberg C, Råstam M, Leboyer M (2009) Psychiatric and 
psychosocial problems in adults with normal-intelligence autism spectrum disorders. 
BMC Psychiatry 9:35 Available at: 
http://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-9-35 [Accessed 
April 29, 2018]. 
Horder J et al. (2018) GABAA receptor availability is not altered in adults with autism 
spectrum disorder or in mouse models. Sci Transl Med 10:eaam8434 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/30282698 [Accessed November 29, 2018]. 
Hornung J-P (2003) The human raphe nuclei and the serotonergic system. J Chem 
Neuroanat 26:331–343 Available at: http://www.ncbi.nlm.nih.gov/pubmed/14729135 
[Accessed April 22, 2014]. 
Humes GE, Welsh MC, Retzlaff P, Cookson N (1997) Towers of Hanoi and London: 
Reliability and Validity of Two Executive Function Tasks. Assessment 4:249–257 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/26613774 [Accessed November 
11, 2020]. 
Ichimiya T, Suhara T, Sudo Y, Okubo Y, Nakayama K, Nankai M, Inoue M, Yasuno F, 
Takano A, Maeda J, Shibuya H (2002) Serotonin transporter binding in patients with 
mood disorders: A PET study with [11C](+)McN5652. Biol Psychiatry 51:715–722 
Available at: https://pubmed.ncbi.nlm.nih.gov/11983185/ [Accessed November 4, 
2020]. 
Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Møller K, Iversen 
M, Banke MB, Petersen IJ, Klingenberg SL, Krogh J, Ebert SE, Timm A, Lindschou J, 
Gluud C (2017) Selective serotonin reuptake inhibitors versus placebo in patients with 
major depressive disorder. A systematic review with meta-analysis and Trial 
Sequential Analysis. BMC Psychiatry 17 Available at: https://pubmed-ncbi-nlm-nih-
gov.proxy.kib.ki.se/28178949/ [Accessed November 13, 2020]. 
 
66 
Jolliffe T, Baron-Cohen S (1997) Are people with autism and Asperger syndrome faster 
than normal on the Embedded Figures Test? J Child Psychol Psychiatry 38:527–534 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/9255696 [Accessed July 21, 
2016]. 
Jurado MB, Rosselli M (2007) The elusive nature of executive functions: A review of our 
current understanding. Neuropsychol Rev 17:213–233 Available at: https://pubmed-
ncbi-nlm-nih-gov.proxy.kib.ki.se/17786559/ [Accessed November 9, 2020]. 
Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, Ustün TB, Wang PS 
(2009) The global burden of mental disorders: an update from the WHO World Mental 
Health (WMH) surveys. Epidemiol Psichiatr Soc 18:23–33 Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3039289&tool=pmcentrez
&rendertype=abstract [Accessed April 6, 2014]. 
Kortte KB, Horner MD, Windham WK (2002) The trail making test, part B: cognitive 
flexibility or ability to maintain set? Appl Neuropsychol 9:106–109 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12214820 [Accessed September 23, 2016]. 
Kuehner C (2017) Why is depression more common among women than among men? The 
Lancet Psychiatry 4:146–158. 
Lai MC, Lombardo M V., Baron-Cohen S (2014) Autism. In: The Lancet, pp 896–910. 
Lancet Publishing Group. Available at: https://pubmed-ncbi-nlm-nih-
gov.proxy.kib.ki.se/24074734/ [Accessed November 6, 2020]. 
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor 
studies. Neuroimage 4:153–158 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9345505 [Accessed February 12, 2016]. 
Lang K, Lopez C, Stahl D, Tchanturia K, Treasure J (2014) Central coherence in eating 
disorders: An updated systematic review and meta-analysis. World J Biol Psychiatry 
15:586–598 Available at: 
http://www.tandfonline.com/doi/full/10.3109/15622975.2014.909606 [Accessed 
September 29, 2020]. 
Larochette AC, Benn K, Harrison AG (2009) Executive functioning: a comparison of the 
Tower of London(DX) and the D-KEFS Tower Test. Appl Neuropsychol 16:275–280 
Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/20183182/ [Accessed 
 
 67 
October 25, 2020]. 
Lefevre A, Mottolese R, Redouté J, Costes N, Le Bars D, Geoffray MM, Leboyer M, Sirigu 
A (2018) Oxytocin fails to recruit serotonergic neurotransmission in the autistic brain. 
Cereb Cortex 28:4169–4178 Available at: 
https://academic.oup.com/cercor/article/28/12/4169/4555261 [Accessed November 6, 
2020]. 
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution 
volume ratios without blood sampling from graphical analysis of PET data. J Cereb 
Blood Flow Metab 16:834–840 Available at: https://pubmed-ncbi-nlm-nih-
gov.proxy.kib.ki.se/8784228/ [Accessed September 20, 2020]. 
Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44:151–
162 Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/9693387/ 
[Accessed November 5, 2020]. 
Lugnegård T, Hallerbäck MU, Gillberg C (2011) Psychiatric comorbidity in young adults 
with a clinical diagnosis of Asperger syndrome. Res Dev Disabil 32:1910–1917 
Available at: http://linkinghub.elsevier.com/retrieve/pii/S0891422211001442 
[Accessed April 29, 2018]. 
Lundström S, Chang Z, Råstam M, Gillberg C, Larsson H, Anckarsäter H, Lichtenstein P 
(2012) Autism spectrum disorders and autisticlike traits. Arch Gen Psychiatry 69:46–
52 Available at: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/1107379 
[Accessed August 25, 2020]. 
Mace S, Taylor D (2000) Selective serotonin reuptake inhibitors: A review of efficacy and 
tolerability in depression. Expert Opin Pharmacother 1:917–933 Available at: 
https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/11249500/ [Accessed November 6, 
2020]. 
Madsen K, Erritzoe D, Mortensen EL, Gade A, Madsen J, Baaré W, Knudsen GM, 
Hasselbalch SG (2011) Cognitive function is related to fronto-striatal serotonin 
transporter levels--a brain PET study in young healthy subjects. Psychopharmacology 
(Berl) 213:573–581 Available at: http://link.springer.com/10.1007/s00213-010-1926-4 
[Accessed October 18, 2019]. 
Makkonen I, Riikonen R, Kokki H, Airaksinen MM, Kuikka JT (2008) Serotonin and 
 
68 
dopamine transporter binding in children with autism determined by SPECT. Dev Med 
Child Neurol 50:593–597 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18754896 [Accessed April 27, 2018]. 
Mannion A, Leader G (2013) Comorbidity in autism spectrum disorder: A literature review. 
Res Autism Spectr Disord 7:1595–1616 Available at: 
https://www.sciencedirect.com/science/article/pii/S1750946713001773 [Accessed 
April 29, 2018]. 
Matheson GJ, Schain M, Almeida R, Lundberg J, Cselényi Z, Borg J, Varrone A, Farde L, 
Cervenka S (2015) Diurnal and seasonal variation of the brain serotonin system in 
healthy male subjects. Neuroimage 112:225–231 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25772667 [Accessed July 8, 2016]. 
Matheson GJ, Stenkrona P, Cselényi Z, Plavén-Sigray P, Halldin C, Farde L, Cervenka S 
(2017) Reliability of volumetric and surface-based normalisation and smoothing 
techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-
23390. Neuroimage 155:344–353 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/28419852 [Accessed March 9, 2020]. 
Matuskey D, Bhagwagar Z, Planeta B, Pittman B, Gallezot J-D, Chen J, Wanyiri J, 
Najafzadeh S, Ropchan J, Geha P, Huang Y, Potenza MN, Neumeister A, Carson RE, 
Malison RT (2014) Reductions in Brain 5-HT1B Receptor Availability in Primarily 
Cocaine-Dependent Humans. Biol Psychiatry 76:816–822 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24433854 [Accessed November 21, 2019]. 
McDevitt R a, Hiroi R, Mackenzie SM, Robin NC, Cohn A, Kim JJ, Neumaier JF (2011) 
Serotonin 1B autoreceptors originating in the caudal dorsal raphe nucleus reduce 
expression of fear and depression-like behavior. Biol Psychiatry 69:780–787 Available 
at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3080128&tool=pmcentrez
&rendertype=abstract [Accessed March 31, 2014]. 
McDougle C, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH (1996) 
Effects of Tryptophan Depletion in Drug-Free Adults With Autistic Disorder. Arch 
Gen Psychiatry 53:993–1000. 
McIntyre RS, Anderson N, Baune BT, Brietzke E, Burdick K, Fossati P, Gorwood P, 
Harmer C, Harrison J, Harvey P, Mansur RB, Medalia A, Miskowiak K, Ramey T, 
 
 69 
Rong C, Rosenblat JD, Young A, Stahl SM (2019) Expert Consensus on Screening 
and Assessment of Cognition in Psychiatry. CNS Spectr 24:154–162. 
Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding V, Kennedy J, 
Wilson AA (2004) Brain Serotonin Transporter Binding Potential Measured With 
Carbon11–Labeled DASB Positron Emission Tomography. Arch Gen Psychiatry 
61:1271 Available at: http://www.ncbi.nlm.nih.gov/pubmed/15583118 [Accessed 
March 30, 2017]. 
Millan MJ et al. (2012) Cognitive dysfunction in psychiatric disorders: characteristics, 
causes and the quest for improved therapy. Nat Rev Drug Discov 11:141–168 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/22293568 [Accessed November 7, 
2017]. 
Murphy DGM, Daly E, Schmitz N, Toal F, Murphy K, Curran S, Erlandsson K, Eersels J, 
Kerwin R, Ell P, Travis M (2006) Cortical serotonin 5-HT2A receptor binding and 
social communication in adults with Asperger’s syndrome: an in vivo SPECT study. 
Am J Psychiatry 163:934–936. 
Murrough JW, Czermak C, Henry S, Nabulsi N, Gallezot J-D, Gueorguieva R, Planeta-
Wilson B, Krystal JH, Neumaier JF, Huang Y, Ding Y-S, Carson RE, Neumeister A 
(2011a) The Effect of Early Trauma Exposure on Serotonin Type 1B Receptor 
Expression Revealed by Reduced Selective Radioligand Binding. Arch Gen Psychiatry 
68:892 Available at: http://www.ncbi.nlm.nih.gov/pubmed/21893657 [Accessed April 
10, 2019]. 
Murrough JW, Henry S, Hu J, Gallezot J-D, Planeta-Wilson B, Neumaier JF, Neumeister A 
(2011b) Reduced ventral striatal/ventral pallidal serotonin1B receptor binding 
potential in major depressive disorder. Psychopharmacology (Berl) 213:547–553 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3139174&tool=pmcentrez
&rendertype=abstract [Accessed March 31, 2014]. 
Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, Tsuchiya KJ, 
Sugihara G, Iwata Y, Suzuki K, Matsuzaki H, Suda S, Sugiyama T, Takei N, Mori N 
(2010) Brain serotonin and dopamine transporter bindings in adults with high-
functioning autism. Arch Gen Psychiatry 67:59–68 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/20048223 [Accessed June 10, 2014]. 
 
70 
Nautiyal KM, Tanaka KF, Barr MM, Tritschler L, Le Dantec Y, David DJ, Gardier AM, 
Blanco C, Hen R, Ahmari SE (2015) Distinct Circuits Underlie the Effects of 5-HT1B 
Receptors on Aggression and Impulsivity. Neuron 86:813–826 Available at: 
https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/25892302/ [Accessed October 17, 
2020]. 
Nautiyal KM, Tritschler L, Ahmari SE, David DJ, Gardier AM, Hen R (2016) A lack of 
serotonin 1B autoreceptors results in decreased anxiety and depression-related 
behaviors. Neuropsychopharmacology 41:2941–2950 Available at: https://pubmed-
ncbi-nlm-nih-gov.proxy.kib.ki.se/27353308/ [Accessed October 17, 2020]. 
Nord M, Finnema SJ, Halldin C, Farde L (2013) Effect of a single dose of escitalopram on 
serotonin concentration in the non-human and human primate brain. Int J 
Neuropsychopharmacol 16:1577–1586 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23351590 [Accessed May 17, 2019]. 
Nord M, Finnema SJ, Schain M, Halldin C, Farde L (2014) Test-retest reliability of 
[11C]AZ10419369 binding to 5-HT(1B) receptors in human brain. Eur J Nucl Med 
Mol Imaging 41:301–307 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24006152 [Accessed March 31, 2014]. 
Nørgaard M, Ganz M, Svarer C, Feng L, Ichise M, Lanzenberger R, Lubberink M, Parsey 
R V, Politis M, Rabiner EA, Slifstein M, Sossi V, Suhara T, Talbot PS, Turkheimer F, 
Strother SC, Knudsen GM (2019) Cerebral serotonin transporter measurements with [ 
11 C]DASB: A review on acquisition and preprocessing across 21 PET centres. J 
Cereb Blood Flow Metab 39:210–222 Available at: 
http://journals.sagepub.com/doi/10.1177/0271678X18770107 [Accessed August 21, 
2019]. 
Oniski KK, Baillargeon R (2005) Do 15-month-old infants understand false beliefs? 
Science (80- ) 308:255–258 Available at: https://pubmed-ncbi-nlm-nih-
gov.proxy.kib.ki.se/15821091/ [Accessed November 1, 2020]. 
Osterrieth PA (1944) Le test de copie d’une figure complexe; contribution à l’étude de la 
perception et de la mémoire. [Test of copying a complex figure; contribution to the 
study of perception and memory]. Arch Psychol (Geneve) 30:206–356 Available at: 
https://psycnet.apa.org/record/1946-02126-001 [Accessed November 15, 2020]. 
Park C, Zuckerman H, Subramaniapillai M, Mansur RB, Rosenblat JD, Cao B, Iacobucci 
 
 71 
M, Lee Y, Levitan R, Blumberger DM, McIntyre RS (2020) Using Early Changes in 
Cold Cognition to Predict Response to Vortioxetine in Major Depressive Disorder. 
Psychiatry Res:112767. 
Penttilä J, Hirvonen J, Tuominen L, Lumme V, Ilonen T, Någren K, Hietala J (2016) 
Verbal memory and 5-HT1A receptors in healthy volunteers – A PET study with 
[carbonyl-11C]WAY-100635. Eur Neuropsychopharmacol 26:570–577 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/26775837 [Accessed May 18, 2018]. 
Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, 
Carpinelli A, Bellodi L, Fazio F (2008) In vivo PET study of 5HT2A serotonin and D2 
dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 
42:306–314 Available at: http://www.ncbi.nlm.nih.gov/pubmed/18511303 [Accessed 
November 15, 2019]. 
Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnäs K, Takano A, 
Karlsson P, Gulyás B, Medd AM, Lee C-M, Powell ME, Heys JR, Potts W, Seneca N, 
Mrzljak L, Farde L, Halldin C (2008) [11C]AZ10419369: a selective 5-HT1B receptor 
radioligand suitable for positron emission tomography (PET). Characterization in the 
primate brain. Neuroimage 41:1075–1085 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18434202 [Accessed March 21, 2014]. 
Porter RJ, Bourke C, Gallagher P (2007) Neuropsychological impairment in major 
depression: its nature, origin and clinical significance. Aust N Z J Psychiatry 41:115–
128 Available at: http://www.ncbi.nlm.nih.gov/pubmed/17464689 [Accessed March 
27, 2014]. 
Rapaport MH, Clary C, Fayyad R, Endicott J (2005) Quality-of-life impairment in 
depressive and anxiety disorders. Am J Psychiatry 162:1171–1178 Available at: 
http://ajp.psychiatryonline.org [Accessed November 12, 2020]. 
Rasmussen H, Erritzoe D, Andersen R, Ebdrup BH, Aggernaes B, Oranje B, Kalbitzer J, 
Madsen J, Pinborg LH, Baaré W, Svarer C, Lublin H, Knudsen GM, Glenthoj B 
(2010) Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients 
with first-episode schizophrenia. Arch Gen Psychiatry 67:9–16 Available at: 
http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/archgenpsychiatry.2009.1
76 [Accessed November 15, 2019]. 
Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, Solbach C, Reischl G, 
 
72 
Schwärzler F, Gründer G, Machulla HJ, Bares R, Heinz A (2008) Anxiety is 
associated with reduced central serotonin transporter availability in unmedicated 
patients with unipolar major depression: A [ 11C]DASB PET study. Mol Psychiatry 
13:606–613 Available at: www.nature.com/mp [Accessed November 4, 2020]. 
Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, Mundt A, Smoltczyk 
HU, Goldman D, Mann K, Reischl G, Machulla HJ, Bares R, Heinz A (2007) Reduced 
availability of serotonin transporters in obsessive-compulsive disorder correlates with 
symptom severity - A [11C]DASB PET study. J Neural Transm 114:1603–1609 
Available at: https://link.springer.com/article/10.1007/s00702-007-0785-6 [Accessed 
November 4, 2020]. 
Reivich M, Amsterdam JD, Brunswick DJ, Yann Shiue C (2004) PET brain imaging with 
[11C](+)McN5652 shows increased serotonin transporter availability in major 
depression. J Affect Disord 82:321–327 Available at: 
https://linkinghub.elsevier.com/retrieve/pii/S0165032704000291 [Accessed November 
4, 2020]. 
Rey A (1941) L’examen psychologique dans les cas d’encéphalopathie traumatique. (Les 
problems.) [The psychological examination in cases of traumatic encepholopathy. 
Problems]. Arch Psychol 28:286–340 Available at: 
https://psycnet.apa.org/record/1943-03814-001 [Accessed November 15, 2020]. 
Rock PL, Roiser JP, Riedel WJ, Blackwell AD (2014) Cognitive impairment in depression: 
a systematic review and meta-analysis. Psychol Med 44:2029–2040 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24168753 [Accessed February 24, 2016]. 
Rosenblat JD, Kakar R, McIntyre RS (2015) The cognitive effects of antidepressants in 
major depressive disorder: a systematic review and meta-analysis of randomized 
clinical trials. Int J Neuropsychopharmacol 19 Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4772818&tool=pmcentrez
&rendertype=abstract [Accessed October 27, 2016]. 
Rosvold HE, Mirsky AF, Sarason I, Bransome ED, Beck LH (1956) A continuous 
performance test of brain damage. J Consult Psychol 20:343–350 Available at: 
/record/1957-07967-001 [Accessed November 14, 2020]. 
Ruf BM, Bhagwagar Z (2009) The 5-HT1B receptor: a novel target for the pathophysiology 




4501&volume=10&issue=11&spage=1118 [Accessed December 12, 2019]. 
Ruff RM, Light RH, Parker SB, Levin HS (1997) The psychological construct of word 
fluency. Brain Lang 57:394–405 Available at: 
https://pubmed.ncbi.nlm.nih.gov/9126423/ [Accessed November 10, 2020]. 
Ruhé HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, 
norepinephrine and dopamine levels in humans: a meta-analysis of monoamine 
depletion studies. Mol Psychiatry 12:331–359 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17389902 [Accessed April 15, 2016]. 
Santos JM, Pousa E, Soto E, Comes A, Roura P, Arrufat FX, Obiols JE (2017) Theory of 
mind in euthymic bipolar patients and first-degree relatives. J Nerv Ment Dis 205:207–
212 Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/27660998/ 
[Accessed September 29, 2020]. 
Sari Y (2004) Serotonin1B receptors: from protein to physiological function and behavior. 
Neurosci Biobehav Rev 28:565–582 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15527863 [Accessed March 27, 2014]. 
Savitz JB, Drevets WC (2009) Imaging phenotypes of major depressive disorder: genetic 
correlates. Neuroscience 164:300–330 Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2760612&tool=pmcentrez
&rendertype=abstract [Accessed March 31, 2014]. 
Savitz JB, Drevets WC (2013) Neuroreceptor imaging in depression. Neurobiol Dis 52:49–
65 Available at: http://www.ncbi.nlm.nih.gov/pubmed/22691454 [Accessed March 31, 
2014]. 
Schain M, Tóth M, Cselényi Z, Arakawa R, Halldin C, Farde L, Varrone A (2013) 
Improved mapping and quantification of serotonin transporter availability in the 
human brainstem with the HRRT. Eur J Nucl Med Mol Imaging 40:228–237 
Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/23076621/ [Accessed 
September 20, 2020]. 
Schain M, Tóth M, Cselényi Z, Stenkrona P, Halldin C, Farde L, Varrone A (2012) 
Quantification of serotonin transporter availability with [11C]MADAM--a comparison 
between the ECAT HRRT and HR systems. Neuroimage 60:800–807 Available at: 
 
74 
http://www.ncbi.nlm.nih.gov/pubmed/22227138 [Accessed September 23, 2015]. 
Schain RJ, Freedman DX (1961) Studies on 5-hydroxyindole metabolism in autistic and 
other mentally retarded children. J Pediatr 58:315–320. 
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of 
supporting evidence. Am J Psychiatry 122:509–522 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/5319766 [Accessed May 22, 2018]. 
Schmid M, Strand M, Ardal G, Lund A, Hammar A (2011) Prolonged impairment in 
inhibition and semantic fluency in a follow-up study of recurrent major depression. 
Arch Clin Neuropsychol 26:677–686 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21700619 [Accessed April 21, 2014]. 
Selvaraj S, Venkatesha Murthy N, Bhagwagar Z, Bose SK, Hinz R, Grasby PM, Cowen PJ 
(2011) Diminished brain 5-HT transporter binding in major depression: a positron 
emission tomography study with [11C]DASB. Psychopharmacology (Berl) 213:555–
562 Available at: http://link.springer.com/10.1007/s00213-009-1660-y [Accessed 
November 15, 2019]. 
Semkovska M, Quinlivan L, O’Grady T, Johnson R, Collins A, O’Connor J, Knittle H, 
Ahern E, Gload T (2019) Cognitive function following a major depressive episode: a 
systematic review and meta-analysis. The Lancet Psychiatry 6:851–861 Available at: 
https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/31422920/ [Accessed November 13, 
2020]. 
Shah A, Frith U (1983) AN ISLET OF ABILITY IN AUTISTIC CHILDREN: A 
RESEARCH NOTE. J Child Psychol Psychiatry 24:613–620 Available at: 
https://acamh.onlinelibrary.wiley.com/doi/full/10.1111/j.1469-7610.1983.tb00137.x 
[Accessed November 14, 2020]. 
Shah A, Frith U (1993) Why Do Autistic Individuals Show Superior Performance on the 
Block Design Task? J Child Psychol Psychiatry 34:1351–1364 Available at: 
https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/8294523/ [Accessed November 11, 
2020]. 
Shallice T (1982) Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 
298:199–209 Available at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/6125971/ 
[Accessed November 11, 2020]. 
 
 75 
Shin M-S, Park S-Y, Park S-R, Seol S-H, Kwon JS (2006) Clinical and empirical 
applications of the Rey–Osterrieth Complex Figure Test. Nat Protoc 1:892–899 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/17406322 [Accessed April 7, 
2017]. 
Simon HA (1975) The functional equivalence of problem solving skills. Cogn Psychol 
7:268–288. 
Sizoo BB, Kuiper E (2017) Cognitive behavioural therapy and mindfulness based stress 
reduction may be equally effective in reducing anxiety and depression in adults with 
autism spectrum disorders. Res Dev Disabil 64:47–55 Available at: https://pubmed-
ncbi-nlm-nih-gov.proxy.kib.ki.se/28342404/ [Accessed November 14, 2020]. 
Snodgrass JG, Smith B, Feenan K, Corwin J (1987) Fragmenting pictures on the apple 
macintosh computer for experimental and clinical applications. Behav Res Methods, 
Instruments, Comput 19:270–274 Available at: 
https://link.springer.com/article/10.3758/BF03203798 [Accessed August 27, 2020]. 
Snyder HR (2013) Major depressive disorder is associated with broad impairments on 
neuropsychological measures of executive function: a meta-analysis and review. 
Psychol Bull 139:81–132 Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3436964&tool=pmcentrez
&rendertype=abstract [Accessed March 19, 2014]. 
Soorya L, Kiarashi J, Hollander E (2008) Psychopharmacologic Interventions for 
Repetitive Behaviors in Autism Spectrum Disorders. Child Adolesc Psychiatr Clin N 
Am 17:753–771. 
Steinbusch HW (1981) Distribution of serotonin-immunoreactivity in the central nervous 
system of the rat-cell bodies and terminals. Neuroscience 6:557–618 Available at: 
https://linkinghub.elsevier.com/retrieve/pii/0306452281901469 [Accessed November 
22, 2019]. 
Stone VE, Baron-Cohen S, Knight RT (1998) Frontal lobe contributions to theory of mind. 
J Cogn Neurosci 10:640–656 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9802997 [Accessed June 7, 2019]. 
Tambs K, Rønning T, Prescott CA, Kendler KS, Reichborn-Kjennerud T, Torgersen S, 
Harris JR (2009) The norwegian institute of public health twin study of mental health: 
 
76 
examining recruitment and attrition bias. Twin Res Hum Genet 12:158–168 Available 
at: https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/19335186/ [Accessed August 11, 
2020]. 
Tangen Ä, Borg J, Tiger M, Varnäs K, Sorjonen K, Lindefors N, Halldin C, Lundberg J 
(2017) Associations between cognition and serotonin receptor 1B binding in patients 
with major depressive disorder - A pilot study. Psychiatry Res 267:15–21 Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0925492716303663 [Accessed July 14, 
2017]. 
Tiger M, Farde L, Rück C, Varrone A, Forsberg A, Lindefors N, Halldin C, Lundberg J 
(2016) Low serotonin1B receptor binding potential in the anterior cingulate cortex in 
drug-free patients with recurrent major depressive disorder. Psychiatry Res 
Neuroimaging 253:36–42 Available at: 
http://www.sciencedirect.com/science/article/pii/S0925492715301426 [Accessed May 
20, 2016]. 
Tiger M, Rück C, Forsberg A, Varrone A, Lindefors N, Halldin C, Farde L, Lundberg J 
(2014) Reduced 5-HT(1B) receptor binding in the dorsal brain stem after cognitive 
behavioural therapy of major depressive disorder. Psychiatry Res Neuroimaging 
223:164–170 Available at: http://www.ncbi.nlm.nih.gov/pubmed/24916155 [Accessed 
December 10, 2014]. 
Tiger M, Varnäs K, Okubo Y, Lundberg J (2018) The 5-HT1B receptor - a potential target 
for antidepressant treatment. Psychopharmacology (Berl) 235:1317–1334 Available at: 
http://link.springer.com/10.1007/s00213-018-4872-1 [Accessed May 10, 2018]. 
Tiger M, Veldman ER, Ekman C-J, Halldin C, Svenningsson P, Lundberg J (2020) A 
randomized placebo-controlled PET study of ketamine´s effect on serotonin1B 
receptor binding in patients with SSRI-resistant depression. Transl Psychiatry 10:159 
Available at: http://www.nature.com/articles/s41398-020-0844-4 [Accessed June 4, 
2020]. 
Tombaugh TN (2004) Trail Making Test A and B: normative data stratified by age and 
education. Arch Clin Neuropsychol 19:203–214 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15010086 [Accessed July 9, 2014]. 
Tombaugh TN, Kozak J, Rees L (1999) Normative data stratified by age and education for 
two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol 
 
 77 
14:167–177 Available at: http://www.ncbi.nlm.nih.gov/pubmed/14590600 [Accessed 
October 10, 2014]. 
Tseng PY, Lee IH, Chen KC, Chen PS, Chiu NT, Yao WJ, Chu CL, Yeh TL, Yang YK 
(2015) The correlation between mid-brain serotonin transporter availability and 
intelligence quotient in healthy volunteers. Eur Psychiatry 30:193–197 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25447350 [Accessed May 23, 2018]. 
Turkheimer FE, Aston JAD, Banati RB, Riddell C, Cunningham VJ (2003) A linear 
wavelet filter for parametric imaging with dynamic PET. IEEE Trans Med Imaging 
22:289–301 Available at: http://www.ncbi.nlm.nih.gov/pubmed/12760547 [Accessed 
February 22, 2016]. 
van der Post J, Schram MT, Schoemaker RC, Pieters MSM, Fuseau E, Pereira A, Baggen S, 
Cohen AF, van Gerven JMA (2002) CNS effects of sumatriptan and rizatriptan in 
healthy female volunteers. Cephalalgia 22:271–281 Available at: 
http://journals.sagepub.com/doi/10.1046/j.1468-2982.2002.00344.x [Accessed 
November 22, 2019]. 
Van Heijst BFC, Geurts HM (2015) Quality of life in autism across the lifespan: A meta-
analysis. Autism 19:158–167 Available at: 
http://journals.sagepub.com/doi/10.1177/1362361313517053 [Accessed November 12, 
2020]. 
Varnäs K, Hall H, Bonaventure P, Sedvall G (2001) Autoradiographic mapping of 5-
HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 
125743. Brain Res 915:47–57 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11578619 [Accessed January 28, 2016]. 
Varnäs K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, Andersson J, McCarthy 
D, Smith M, Pierson ME, Söderström J, Farde L (2011) Quantitative analysis of 
[11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow 
Metab 31:113–123 Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3049476&tool=pmcentrez
&rendertype=abstract [Accessed April 29, 2014]. 
Varrone A, Svenningsson P, Marklund P, Fatouros-Bergman H, Forsberg A, Halldin C, 
Nilsson L-G, Farde L (2015) 5-HT1B receptor imaging and cognition: a positron 
emission tomography study in control subjects and Parkinson’s disease patients. 
 
78 
Synapse 69:365–374 Available at: http://www.ncbi.nlm.nih.gov/pubmed/25914348 
[Accessed October 21, 2016]. 
Veenstra-VanderWeele J et al. (2012) Autism gene variant causes hyperserotonemia, 
serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc 
Natl Acad Sci U S A 109:5469–5474 Available at: 
http://www.pnas.org/cgi/doi/10.1073/pnas.1112345109 [Accessed May 6, 2018]. 
Vicent-Gil M, Keymer-Gausset A, Serra-Blasco M, Carceller-Sindreu M, de Diego-Adeliño 
J, Trujols J, Mur M, Pérez V, Alvarez E, Cardoner N, Portella MJ (2018) Cognitive 
predictors of illness course at 12 months after first-episode of depression. Eur 
Neuropsychopharmacol 28:529–537. 
Whitaker-Azmitia PM (2001) Serotonin and brain development: Role in human 
developmental diseases. Brain Res Bull 56:479–485 Available at: https://pubmed-
ncbi-nlm-nih-gov.proxy.kib.ki.se/11750793/ [Accessed November 1, 2020]. 
Wienhard K, Schmand M, Casey ME, Baker K, Bao J, Eriksson L, Jones WF, Knoess C, 
Lenox M, Lercher M, Luk P, Michel C, Reed JH, Richerzhagen N, Treffert J, Vollmar 
S, Young JW, Heiss WD, Nutt R (2002) The ECAT HRRT: Performance and first 
clinical application of the new high resolution research tomograph. IEEE Trans Nucl 
Sci 49:104–110. 
Witkin HA, Oltman PK, Raskin E, Karp SA (1971) A manual for the embedded figure 
tests. Palo Alto, CA: Consulting Psychogist Press. 
Wolff M, Savova M, Malleret G, Hen R, Segu L, Buhot M-C (2003) Serotonin 1B 
knockout mice exhibit a task-dependent selective learning facilitation. Neurosci Lett 
338:1–4 Available at: http://www.ncbi.nlm.nih.gov/pubmed/12565126 [Accessed May 
12, 2016]. 
World Health Organization (2004) The Global Burden of Disease: 2004 Update. 
World Health Organization (2017) Depression and other common mental disorders: global 
health estimates. Geneva, Switzerland. 
Yasuno F, Suhara T, Nakayama T, Ichimiya T, Okubo Y, Takano A, Ando T, Inoue M, 
Maeda J, Suzuki K (2003) Inhibitory effect of hippocampal 5-HT1A receptors on 
human explicit memory. Am J Psychiatry 160:334–340 Available at: https://pubmed-
ncbi-nlm-nih-gov.proxy.kib.ki.se/12562581/ [Accessed October 19, 2020]. 
 
 79 
Zimmerman M, McGlinchey JB, Young D, Chelminski I (2006) Diagnosing Major 
Depressive Disorder I. J Nerv Ment Dis 194:158–163 Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16534432 [Accessed December 21, 2017]. 
 
